Publications

Publications of the Institute of Cell Biology and Immunology

Publications of the Institute

  1. 2026

    1. Mora-Molina, R., El Yousfi, Y., Hagenlocher, C., Fernández-Farrán, F. J., Rehm, M., Palacios, C., Christophorou, M. A., & López-Rivas, A. (2026). REDD1/DDIT4 counteracts endoplasmic reticulum stress-induced apoptosis by controlling the expression of death receptor TRAILR2/DR5 in cancer cells. Cell Death & Disease. https://doi.org/10.1038/s41419-026-08648-7
    2. Asmanidou, S., Thiel, J., Ekstrom, T. L., Schueler, J., Oswald, E., Metzger, P., Blaumeiser, A. C., Boerries, M., Wiebl, L.-M., Schiffler, R., Tamas, R., Essmann, F., Dong, M., Johnsen, S. A., Kontermann, R. E., & Olayioye, M. A. (2026). BCL-xL as a therapeutic target in cetuximab-refractory colorectal cancer. Cell Death & Disease, 17, Article 1. https://doi.org/10.1038/s41419-026-08434-5
    3. Klötzer, F., Pollak, N., Baatz, A., Kisakol, B., Ginty, F., Longley, D. B., Prehn, J. H. M., & Rehm, M. (2026). Spatiotemporal dynamics of Mcl-1 abundance and its influence on apoptosis susceptibility. bioRxiv. https://doi.org/10.64898/2026.02.06.704006
    4. Hüther, J. A., Mallais, M., Rehm, M., & Pratt, D. A. (2026). Implementation of the FENIX assay to screen for and assess inhibitors of lipid peroxidation and associated ferroptosis. Methods in Cell Biology. https://doi.org/10.1016/bs.mcb.2026.01.013

  2. 2025

    1. Höpfl, S., Özverin, M., Nowack, H., Tamas, R., Clark, A. G., Radde, N., & Olayioye, M. A. (2025). Integrated mathematical and experimental modeling uncovers enhanced EMT plasticity upon loss of the DLC1 tumor suppressor. PLOS Computational Biology, 21, Article 5. https://doi.org/10.1371/journal.pcbi.1013076
    2. Geiger, J., Klötzer, F., Pollak, N., Fullstone, G., & Rehm, M. (2025). Stochasticity contributes to explaining minority and majority MOMP during apoptosis. Cell Death & Disease, 16, Article 1. https://doi.org/10.1038/s41419-025-08258-9
    3. Möller, A. M., Vettermann, S., Baumann, F., Pütter, M., & Müller, D. (2025). Trifunctional antibody-cytokine fusion protein formats for tumor-targeted combination of IL-15 with IL-7 or IL-21. Frontiers in Immunology, Volume 16 - 2025. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1498697
    4. Blum, J., Brüll, M., Hengstler, J. G., Dietrich, D. R., Gruber, A. J., Dipalo, M., Kraushaar, U., Mangas, I., Terron, A., Fritsche, E., Marx-Stoelting, P., Hardy, B., Schepky, A., Escher, S., Hartung, T., Landsiedel, R., Odermatt, A., Sachana, M., Koch, K., et al. (2025). The long way from raw data to NAM-based information: Overview on data layers and processing steps. ALTEX - Alternatives to Animal Experimentation, 42, Article 1. https://doi.org/10.14573/altex.2412171
    5. Pegoretti, V., Boerema, A., Kats, K., Dafauce Garcia, J. M., Fischer, R., Kontermann, R. E., Pfizenmaier, K., Laman, J. D., Eisel, U. L. M., & Baron, W. (2025). Single intracerebroventricular TNFR2 agonist injection impacts remyelination in the cuprizone model. Journal of Molecular Medicine (Berlin, Germany), 10. https://doi.org/10.1007/s00109-025-02549-6
    6. Kuhn, P., Petralla, S., Dabbagh, F., Pegoretti, V., Muranyi, W., Ishikawa, H., Schroten, H., Fischer, R., Frenzel, A., Schirrmann, T., Rehm, M., Schwerk, C., Fricker, G., Kontermann, R., & Fullstone, G. (2025). A pH-sensitive binding modality allows successful transferrin receptor-mediated transcytosis of a bivalent antibody across brain barriers. mAbs, 17, Article 1. https://doi.org/10.1080/19420862.2025.2563758
    7. Lieb, W. S., Oueslati Morales, C. O., Ellwanger, K., Koch, C., Lutz, S., Eisler, S. A., Möller, A. M., Leiss, V., & Hausser, A. (2025). Protein Kinase D deficiency induces a senescence-like phenotype in β-cells and improves glucose and insulin tolerance under high-fat diet conditions. Molecular Metabolism, 102297. https://doi.org/10.1016/j.molmet.2025.102297
    8. Gutiérrez-Galindo, E., Jursik, K., Frey, Y., Meyer, F., & Hausser, A. (2025). PKD3 localizes to late endosomes to maintain Rab7-dependent endolysosomal homeostasis. iScience, 28, Article 9. https://doi.org/10.1016/j.isci.2025.113408
    9. Michler, D., Seifert, O., Pfizenmaier, K., & Kontermann, R. E. (2025). Comparison of antibody-scTRAIL Fc fusion proteins with varying valency for EGFR and TRAIL receptors. Scientific Reports, 15, Article 1. https://doi.org/10.1038/s41598-025-00476-7
    10. Qiu, Y., Hüther, J. A., Wank, B., Rath, A., Tykwe, R., Aldrovandi, M., Henkelmann, B., Mergner, J., Nakamura, T., Laschat, S., Conrad, M., Stöhr, D., & Rehm, M. (2025). Interplay of ferroptotic and apoptotic cell death and its modulation by BH3-mimetics. Cell Death & Differentiation. https://doi.org/10.1038/s41418-025-01514-7
    11. Wienken, K., Mazur, A., Gericke, B., Petralla, S., Wagner, L., Seifert, O., Kontermann, R. E., & Fricker, G. (2025). Immunoliposomes - a new therapeutic option to treat SynGAP1-associated epilepsy. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V, 114799. https://doi.org/10.1016/j.ejpb.2025.114799
    12. Pelzer, N., Lukic, T., Ge, W., Schnabel, N., Teufel, P., Olayioye, M. A., Najafova, Z., & Lungu, C. (2025). PHF19 drives the formation of PRC2 clusters to enhance motility in TNBC cells. Cell Reports, 44, Article 10. https://doi.org/10.1016/j.celrep.2025.116391
    13. Löffler, A.-K., Huber, A., Olayioye, M. A., Kontermann, R. E., & Seifert, O. (2025). Trispecific eFab-eIg T-cell engagers targeting HER2 and HER3. Frontiers in Immunology, Volume 16 - 2025. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1642454
    14. Meyer, F., Lungu, C., Noll, B., Benz, D., Fränkle, F., Ferreira, M. Â., Tamas, R., & Olayioye, M. A. (2025). Reciprocal regulation of Solo and Src orchestrates Src trafficking to promote mesenchymal cell migration. iScience, 28, Article 6. https://doi.org/10.1016/j.isci.2025.112618

  3. 2024

    1. Holland, J., Lungu, C., Weber, R., Emperle, M., & Graf, T. (2024). Impact of repetitive, ultra-short soft X-ray pulses from processing of steel with ultrafast lasers on human cell cultures. Applied Physics A, 130, Article 12. https://doi.org/10.1007/s00339-024-08134-x
    2. Klein, C., Brinkmann, U., Reichert, J. M., & Kontermann, R. E. (2024). The present and future of bispecific antibodies for cancer therapy. Nature Reviews Drug Discovery, 23, Article 4. https://doi.org/10.1038/s41573-024-00896-6
    3. Yang, H., Meyer, F., Huang, S., Yang, L., Lungu, C., Olayioye, M. A., Buehler, M. J., & Guo, M. (2024). Learning Collective Cell Migratory Dynamics from a Static Snapshot with Graph Neural Networks. PRX Life, 2, Article 4. https://doi.org/10.1103/PRXLife.2.043010
    4. Köhler, A. R., Haußer, J., Harsch, A., Bernhardt, S., Häußermann, L., Brenner, L.-M., Lungu, C., Olayioye, M. A., Bashtrykov, P., & Jeltsch, A. (2024). Modular dual-color BiAD sensors for locus-specific readout of epigenome modifications in single cells. Cell Reports Methods, 4, Article 4. https://doi.org/10.1016/j.crmeth.2024.100739
    5. Entrop, K., Wieske, S., & Rehm, M. (2024). Why Bax detection in >1400 publications might be flawed. Cell Death & Disease, 15, Article 12. https://doi.org/10.1038/s41419-024-07273-6
    6. Boccellato, C., & Rehm, M. (2024). TRAIL-induced apoptosis and proteasomal activity – Mechanisms, signalling and interplay. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 119688. https://doi.org/10.1016/j.bbamcr.2024.119688
    7. Gali, A., Bijnsdorp, I. V., Piersma, S. R., Pham, T. V., Gutiérrez-Galindo, E., Kühnel, F., Tsolakos, N., Jimenez, C. R., Hausser, A., & Alexopoulos, L. G. (2024). Protein Kinase D drives the secretion of invasion mediators in triple-negative breast cancer cell lines. iScience, 108958. https://doi.org/10.1016/j.isci.2024.108958
    8. Brenner, L.-M., Meyer, F., Yang, H., Köhler, A. R., Bashtrykov, P., Guo, M., Jeltsch, A., Lungu, C., & Olayioye, M. A. (2024). Repeat DNA methylation is modulated by adherens junction signaling. Communications Biology, 7, Article 1. https://doi.org/10.1038/s42003-024-05990-4
    9. Frey, Y., Lungu, C., & Olayioye, M. A. (2024). Regulation and functions of the DLC family of RhoGAP proteins: Implications for development and cancer. Cellular Signalling, 125, 111505. https://doi.org/10.1016/j.cellsig.2024.111505
    10. Schlett, K., Oueslati Morales, C. O., Bencsik, N., & Hausser, A. (2024). Getting smart – Deciphering the neuronal functions of protein kinase D. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1871, Article 7. https://doi.org/10.1016/j.bbamcr.2024.119812
    11. Frey, Y., Lungu, C., Meyer, F., Hauth, F., Hahn, D., Kersten, C., Heller, V., Franz-Wachtel, M., Macek, B., Barsukov, I., & Olayioye, M. A. (2024). Regulation of the DLC3 tumor suppressor by a novel phosphoswitch. iScience, 27, Article 7. https://doi.org/10.1016/j.isci.2024.110203
    12. Beigl, T. B., Paul, A., Fellmeth, T. P., Nguyen, D., Barber, L., Weller, S., Schäfer, B., Gillissen, B. F., Aulitzky, W. E., Kopp, H.-G., Rehm, M., Andrews, D. W., Pluhackova, K., & Essmann, F. (2024). BCL-2 and BOK regulate apoptosis by interaction of their C-terminal transmembrane domains. EMBO Reports, 25, Article 9. https://doi.org/10.1038/s44319-024-00206-6
    13. Nguyen, K. L., Bhatt, I. J., Gupta, S., Showkat, N., Swanson, K. A., Fischer, R., Kontermann, R. E., Pfizenmaier, K., Bracchi-Ricard, V., & Bethea, J. R. (2024). Tumor necrosis factor receptor 2 activation elicits sex-specific effects on cortical myelin proteins and functional recovery in a model of multiple sclerosis. Brain Research Bulletin, 207, 110885. https://doi.org/10.1016/j.brainresbull.2024.110885

  4. 2023

    1. Gutiérrez-Galindo, E., Yilmaz, Z. H., & Hausser, A. (2023). Membrane trafficking in breast cancer progression: protein kinase D comes into play. Frontiers in Cell and Developmental Biology, 11, 1173387. https://doi.org/10.3389/fcell.2023.1173387
    2. Guttà, C., Morhard, C., & Rehm, M. (2023). Applying a GAN-based classifier to improve transcriptome-based prognostication in breast cancer. PLOS Computational Biology, 19, Article 4. https://doi.org/10.1371/journal.pcbi.1011035
    3. Reinhardt, R., Hirzel, K., Link, G., Eisler, S. A., Hägele, T., Parson, M. A. H., Burke, J. E., Hausser, A., & Leonard, T. A. (2023). PKD autoinhibition in trans regulates activation loop autophosphorylation in cis. Proceedings of the National Academy of Sciences, 120, Article 7. https://doi.org/10.1073/pnas.2212909120
    4. Liang, K. L., Roels, J., Lavaert, M., Putteman, T., Boehme, L., Tilleman, L., Velghe, I., Pegoretti, V., Van de Walle, I., Sontag, S., Vandewalle, J., Vandekerckhove, B., Leclercq, G., Van Vlierberghe, P., Libert, C., Van Nieuwerburgh, F., Fischer, R., Kontermann, R. E., Pfizenmaier, K., et al. (2023). Intrathymic dendritic cell-biased precursors promote human T cell lineage specification through IRF8-driven transmembrane TNF. Nature Immunology. https://doi.org/10.1038/s41590-022-01417-6
    5. Fiedler, T., Fairless, R., Pichi, K., Fischer, R., Richter, F., Kontermann, R. E., Pfizenmaier, K., Diem, R., & Williams, S. K. (2023). Co-modulation of TNFR1 and TNFR2 in an animal model of multiple sclerosis. Journal of Neuroinflammation, 20, Article 1. https://doi.org/10.1186/s12974-023-02784-z
    6. Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., Aqeilan, R. I., Arama, E., Baehrecke, E. H., Balachandran, S., Bano, D., Barlev, N. A., Bartek, J., et al. (2023). Apoptotic cell death in disease---Current understanding of the NCCD 2023. Cell Death & Differentiation, 30, Article 5. https://doi.org/10.1038/s41418-023-01153-w
    7. Abassi, L., Bertoglio, F., Mačak Šafranko, Ž., Schirrmann, T., Greweling-Pils, M., Seifert, O., Khan, F., Katzmarzyk, M., Jacobsen, H., Gödecke, N., Heine, P. A., Frenzel, A., Nowack, H., Dübel, S., Kurolt, I.-C., Kontermann, R. E., Markotić, A., Schubert, M., Hust, M., & Čičin-Šain, L. (2023). Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns. Viruses, 15, Article 11. https://doi.org/10.3390/v15112153
    8. Müller, D. (2023). Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy. BioDrugs, 37, Article 1. https://doi.org/10.1007/s40259-022-00573-3
    9. Kühl, L., Schäfer, A. K., Kraft, S., Aschmoneit, N., Kontermann, R. E., & Seifert, O. (2023). eIg-based bispecific T-cell engagers targeting EGFR: Format matters. mAbs, 15, Article 1. https://doi.org/10.1080/19420862.2023.2183540
    10. Ortí-Casañ, N., Boerema, A. S., Köpke, K., Ebskamp, A., Keijser, J., Zhang, Y., Chen, T., Dolga, A. M., Broersen, K., Fischer, R., Pfizenmaier, K., Kontermann, R. E., & Eisel, U. L. M. (2023). The TNFR1 antagonist Atrosimab reduces neuronal loss, glial activation and memory deficits in an acute mouse model of neurodegeneration. Scientific Reports, 13, Article 1. https://doi.org/10.1038/s41598-023-36846-2
    11. Ignácz, A., Nagy-Herczeg, D., Hausser, A., & Schlett, K. (2023). Dendritic effects of genetically encoded actin labelling probes in cultured hippocampal neurons. Molecular Biology of the Cell. https://doi.org/10.1091/mbc.e22-08-0331
    12. Lungu, C., Meyer, F., Hörning, M., Steudle, J., Braun, A., Noll, B., Benz, D., Fränkle, F., Schmid, S., Eisler, S. A., Olayioye, M. A., & Monilola Olayioye, C. A. (2023). Golgi screen identifies the RhoGEF Solo as a novel regulator of RhoB and endocytic transport. Traffic. https://doi.org/10.1111/TRA.12880
    13. Fullstone, G. (2023). Rapid Particle-Based Simulations of Cellular Signalling with the FLAME-Accelerated Signalling Tool (FaST) and GPUs. In Computational Modeling of Signaling Networks (pp. 191–212). Springer US. https://doi.org/10.1007/978-1-0716-3008-2_9

  5. 2022

    1. Müller, D. (2022). Optimized CD19/CD22/CD3 antibody. Blood, 140, Article 16. https://doi.org/10.1182/blood.2022018081
    2. Dilchert, J., Hofmann, M., Unverdorben, F., Kontermann, R., & Bunk, S. (2022). Mammalian Display Platform for the Maturation of Bispecific TCR-Based Molecules. Antibodies, 11, Article 2. https://doi.org/10.3390/antib11020034
    3. Hagenlocher, C., Siebert, R., Taschke, B., Wieske, S., Hausser, A., & Rehm, M. (2022). ER stress-induced cell death proceeds independently of the TRAIL-R2 signaling axis in pancreatic β cells. Cell Death Discovery, 8, Article 1. https://doi.org/10.1038/s41420-022-00830-y
    4. Bencsik, N., Oueslati Morales, C. O., Hausser, A., & Schlett, K. (2022). Endocytosis of AMPA receptors: Role in neurological conditions. Academic Press. https://doi.org/10.1016/bs.pmbts.2022.09.007
    5. Guttà, C., Morhard, C., & Rehm, M. (2022). Applying GAN-based data augmentation to improve transcriptome-based prognostication in breast cancer. In medRxiv. Cold Spring Harbor Laboratory Press. https://doi.org/10.1101/2022.10.07.22280776
    6. Mora-Molina, R., Stöhr, D., Rehm, M., & López-Rivas, A. (2022). cFLIP downregulation is an early event required for endoplasmic reticulum stress-induced apoptosis in tumor cells. Cell Death & Disease, 13, Article 2. https://doi.org/10.1038/s41419-022-04574-6
    7. Aschmoneit, N., Kocher, K., Siegemund, M., Lutz, M. S., Kühl, L., Seifert, O., & Kontermann, R. E. (2022). Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc). Oncoimmunology, 11, Article 1. https://doi.org/10.1080/2162402X.2022.2028961
    8. Guttà, C., Morhard, C., & Rehm, M. (2022, October). T-GAN-D: a GAN-based classifier for breast cancer prognostication [Zenodo]. https://doi.org/10.5281/zenodo.7151831
    9. Rau, A., Janssen, N., Kühl, L., Sell, T., Kalmykova, S., Mürdter, T. E., Dahlke, M.-H., Sers, C., Morkel, M., Schwab, M., Kontermann, R. E., & Olayioye, M. A. (2022). Triple targeting of HER receptors overcomes heregulin-mediated resistance to EGFR blockade in colorectal cancerTriple HER blockade in CRC. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.MCT-21-0818
    10. Del Mistro, G., Riemann, S., Schindler, S., Beissert, S., Kontermann, R. E., Ginolhac, A., Halder, R., Presta, L., Sinkkonen, L., Sauter, T., & Kulms, D. (2022). Focal adhesion kinase plays a dual role in TRAIL resistance and metastatic outgrowth of malignant melanoma. Cell Death & Disease, 13, Article 1. https://doi.org/10.1038/s41419-022-04502-8
    11. Boccellato, C., & Rehm, M. (2022). Glioblastoma, from disease understanding towards optimal cell-based in vitro models. Cellular Oncology. https://doi.org/10.1007/s13402-022-00684-7
    12. Frey, Y., Franz-Wachtel, M., Macek, B., & Olayioye, M. A. (2022). Proteasomal turnover of the RhoGAP tumor suppressor DLC1 is regulated by HECTD1 and USP7. Scientific Reports 2022 12:1, 12, Article 1. https://doi.org/10.1038/s41598-022-08844-3

  6. 2021

    1. Oueslati Morales, C. O., Ignácz, A., Bencsik, N., Sziber, Z., Rátkai, A. E., Lieb, W. S., Eisler, S. A., Szűcs, A., Schlett, K., & Hausser, A. (2021). Protein Kinase D promotes activity-dependent AMPA receptor endocytosis in hippocampal neurons. Traffic, n/a, Article n/a. https://doi.org/10.1111/tra.12819
    2. Aschmoneit, N., Steinlein, S., Kühl, L., Seifert, O., & Kontermann, R. E. (2021). A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells. Scientific Reports, 11, Article 1. https://doi.org/10.1038/S41598-021-93351-0
    3. Brinkmann, U., & Kontermann, R. E. (2021). Bispecific antibodies. Science, 372, Article 6545. https://doi.org/10.1126/science.abg1209
    4. Richter, F., Williams, S. K., John, K., Huber, C., Vaslin, C., Zanker, H., Fairless, R., Pichi, K., Marhenke, S., Vogel, A., Dhaen, M.-A., Herrmann, S., Herrmann, A., Pfizenmaier, K., Bantel, H., Diem, R., Kontermann, R. E., & Fischer, R. (2021). The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.705485
    5. Massafra, V., Tundo, S., Dietzig, A., Ducret, A., Jost, C., Klein, C., Kontermann, R. E., Knoetgen, H., Steegmaier, M., Romagnani, A., & Nagel, Y. A. (2021). Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2000252
    6. Hellwig, C. T., Delgado, M. E., Skoko, J., Dyck, L., Hanna, C., Wentges, A., Langlais, C., Hagenlocher, C., Mack, A., Dinsdale, D., Cain, K., MacFarlane, M., & Rehm, M. (2021). Proteasome inhibition triggers the formation of TRAIL receptor 2 platforms for caspase-8 activation that accumulate in the cytosol. Cell Death & Differentiation 2021, 1–9. https://doi.org/10.1038/s41418-021-00843-7
    7. Juric, V., Düssmann, H., Lamfers, M. L. M., Prehn, J. H. M., Rehm, M., & Murphy, B. M. (2021). Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM. Cells 2021, Vol. 10, Page 1182, 10, Article 5. https://doi.org/10.3390/cells10051182
    8. Lindner, A. U., Salvucci, M., McDonough, E., Cho, S., Stachtea, X., O’Connell, E. P., Corwin, A. D., Santamaria-Pang, A., Carberry, S., Fichtner, M., Van Schaeybroeck, S., Laurent-Puig, P., Burke, J. P., McNamara, D. A., Lawler, M., Sood, A., Graf, J. F., Rehm, M., Dunne, P. D., et al. (2021). An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution. Cell Death & Differentiation. https://doi.org/10.1038/s41418-021-00895-9
    9. Ehlers, W., Morrison (Rehm), M., Schröder, P., Stöhr, D., & Wagner, A. (2021). Multiphasic modelling and computation of metastatic lung-cancer cell proliferation and atrophy in brain tissue based on experimental data. Biomechanics and Modeling in Mechanobiology. https://doi.org/10.1007/s10237-021-01535-4
    10. Bethea, J. R., & Fischer, R. (2021). Role of peripheral immune cells for development and recovery of chronic pain. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.641588
    11. McCann, C., Matveeva, A., McAllister, K., Sessler, T., Fichtner, M., Carberry, S., Rehm, M., Prehn, J. H. M., & Longley, D. B. (2021). Development of a protein signature to enable clinical positioning of IAP inhibitors in colorectal cancer. The FEBS Journal, febs. https://doi.org/10.1111/febs.15801
    12. Juric, V., Hudson, L., Fay, J., Richards, C. E., Jahns, H., Verreault, M., Bielle, F., Idbaih, A., Lamfers, M. L. M., Hopkins, A. M., Rehm, M., & Murphy, B. M. (2021). Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation. Cell Death & Disease 2021 12:8, 12, Article 8. https://doi.org/10.1038/s41419-021-04050-7

  7. 2020

    1. Sánchez-González, I., Bobien, A., Molnar, C., Schmid, S., Strotbek, M., Boerries, M., Busch, H., & Olayioye, M. A. (2020). miR-149 suppresses breast cancer metastasis by blocking paracrine interactions with macrophages. Cancer Research, canres. https://doi.org/10.1158/0008-5472.CAN-19-1934
    2. Tansi, F. L., Rüger, R., Kollmeier, A. M., Rabenhold, M., Steiniger, F., Kontermann, R. E., Teichgräber, U. K., Fahr, A., & Hilger, I. (2020). Targeting the Tumor Microenvironment with Fluorescence-Activatable Bispecific Endoglin/Fibroblast Activation Protein Targeting Liposomes. Pharmaceutics, 12, Article 4. https://doi.org/10.3390/pharmaceutics12040370
    3. Pegoretti, V., Swanson, K. A., Bethea, J. R., Probert, L., Eisel, U. L. M., & Fischer, R. (2020). Inflammation and Oxidative Stress in Multiple Sclerosis: Consequences for Therapy Development. Oxidative Medicine and Cellular Longevity, 2020, 19. https://doi.org/10.1155/2020/7191080
    4. Stöhr, D., Schmid, J. O., Beigl, T. B., Mack, A., Maichl, D. S., Cao, K., Budai, B., Fullstone, G., Kontermann, R. E., Mürdter, T. E., Tait, S. W. G., Hagenlocher, C., Pollak, N., Scheurich, P., & Rehm, M. (2020). Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids. Cell Death & Differentiation. https://doi.org/10.1038/s41418-020-0559-3
    5. Rau, A., Lieb, W. S., Seifert, O., Honer, J., Birnstock, D., Richter, F., Aschmoneit, N., Olayioye, M. A., & Kontermann, R. E. (2020). Inhibition of tumor cell growth and cancer stem cell expansion by a bispecific antibody targeting EGFR and HER3. Mol Cancer Ther. https://doi.org/10.1158/1535-7163.MCT-19-1095
    6. Imig, D., Pollak, N., Allgöwer, F., & Rehm, M. (2020). Sample-based modeling reveals bidirectional interplay between cell cycle progression and extrinsic apoptosis. PLOS Computational Biology, 16, Article 6. https://doi.org/10.1371/journal.pcbi.1007812
    7. White, K., Connor, K., Clerkin, J., Murphy, B. M., Salvucci, M., O’Farrell, A. C., Rehm, M., O’Brien, D., Prehn, J. H. M., Niclou, S. P., Lamfers, M. L. M., Verreault, M., Idbaih, A., Verhaak, R., Golebiewska, A., & Byrne, A. T. (2020). New hints towards a precision medicine strategy for IDH wild-type Glioblastoma. Annals of Oncology. https://doi.org/10.1016/j.annonc.2020.08.2336
    8. Müller, I., Strozyk, E., Schindler, S., Beissert, S., Oo, H. Z., Sauter, T., Lucarelli, P., Raeth, S., Hausser, A., Al Nakouzi, N., Fazli, L., Gleave, M. E., Liu, H., Simon, H.-U., Walczak, H., Green, D. R., Bartek, J., Daugaard, M., & Kulms, D. (2020). Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28. Molecular Cell. https://doi.org/10.1016/j.molcel.2019.12.023
    9. Vetma, V., Guttà, C., Peters, N., Praetorius, C., Hutt, M., Seifert, O., Meier, F., Kontermann, R., Kulms, D., & Rehm, M. (2020). Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism. Cell Death & Differentiation 2020, 1–16. https://doi.org/10.1038/s41418-020-0512-5
    10. Guttà, C., Rahman, A., Aura, C., Dynoodt, P., Charles, E. M., Hirschenhahn, E., Joseph, J., Wouters, J., de Chaumont, C., Rafferty, M., Warren, M., van den Oord, J. J., Gallagher, W. M., & Rehm, M. (2020). Low expression of pro-apoptotic proteins Bax, Bak and Smac indicates prolonged progression-free survival in chemotherapy-treated metastatic melanoma. Cell Death & Disease, 11, Article 2. https://doi.org/10.1038/s41419-020-2309-3
    11. Zhang, S., Liu, H., Yin, M., Pei, X., Hausser, A., Ishikawa, E., Yamasaki, S., & Jin, Z. G. (2020). Deletion of Protein Kinase D3 Promotes Liver Fibrosis in Mice. Hepatology, hep. https://doi.org/10.1002/hep.31176
    12. Khawaja, H., Campbell, A., Roberts, J. Z., Javadi, A., O’Reilly, P., McArt, D., Allen, W. L., Majkut, J., Rehm, M., Bardelli, A., Di Nicolantonio, F., Scott, C. J., Kennedy, R., Vitale, N., Harrison, T., Sansom, O. J., Longley, D. B., Evergren, E., & Van Schaeybroeck, S. (2020). RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer. Cell Death & Disease, 11, Article 10. https://doi.org/10.1038/s41419-020-03131-3
    13. Stöhr, D., & Rehm, M. (2020). Linking hyperosmotic stress and apoptotic sensitivity. The FEBS Journal, febs. https://doi.org/10.1111/febs.15520
    14. Fischer, R., Kontermann, R. E., & Pfizenmaier, K. (2020). Selective targeting of TNF receptors as a novel therapeutic approach. Frontiers in Cell and Developmental Biology, 8. https://doi.org/10.3389/fcell.2020.00401
    15. Sapski, S., Beha, N., Kontermann, R. E., & Müller, D. (2020). Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-020-02624-6
    16. Stöhr, D., Jeltsch, A., & Rehm, M. (2020). TRAIL receptor signaling: From the basics of canonical signal transduction toward its entanglement with ER stress and the unfolded protein response. Int Rev Cell Mol Biol, 351, 57–99. https://doi.org/10.1016/bs.ircmb.2020.02.002
    17. Wandrer, F., Liebig, S., Marhenke, S., Vogel, A., John, K., Manns, M. P., Teufel, A., Itzel, T., Longerich, T., Maier, O., Fischer, R., Kontermann, R. E., Pfizenmaier, K., Schulze-Osthoff, K., & Bantel, H. (2020). TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. Cell Death Dis, 11, Article 3. https://doi.org/10.1038/s41419-020-2411-6
    18. Fullstone, G., Guttà, C., Beyer, A., & Rehm, M. (2020). The FLAME-accelerated signalling tool (FaST) for facile parallelisation of flexible agent-based models of cell signalling. Npj Systems Biology and Applications, 6, Article 1. https://doi.org/10.1038/s41540-020-0128-x
    19. Kuritz, K., Stöhr, D., Maichl, D. S., Pollak, N., Rehm, M., & Allgöwer, F. (2020). Reconstructing temporal and spatial dynamics from single-cell pseudotime using prior knowledge of real scale cell densities. Scientific Reports, 10, Article 1. https://doi.org/10.1038/s41598-020-60400-z
    20. Hartung, F., Krüwel, T., Shi, X., Pfizenmaier, K., Kontermann, R., Chames, P., Alves, F., & Pardo, L. A. (2020). A Novel Anti-Kv10.1 Nanobody Fused to Single-Chain TRAIL Enhances Apoptosis Induction in Cancer Cells. Front Pharmacol, 11, 686. https://doi.org/10.3389/fphar.2020.00686
    21. Fullstone, G., Bauer, T. L., Guttà, C., Salvucci, M., Prehn, J. H. M., & Rehm, M. (2020). The apoptosome molecular timer synergises with XIAP to suppress apoptosis execution and contributes to prognosticating survival in colorectal cancer. Cell Death & Differentiation. https://doi.org/10.1038/s41418-020-0545-9
    22. Fabre, M., Ferrer, C., Dominguez-Hormaetxe, S., Bockorny, B., Murias, L., Seifert, O., Eisler, S. A., Kontermann, R. E., Pfizenmaier, K., Lee, S. Y., dM Vivanco, M., Lopez-Casas, P. P., Perea, S., Abbas, M., Richter, W., Simón, L., & Hidalgo, M. (2020). OMTX705, a Novel FAP-Targeting ADC demonstrates Activity in Chemotherapy and PD1-Resistant Solid Tumors Models. Clinical Cancer Research, clincanres. https://doi.org/10.1158/1078-0432.CCR-19-2238

  8. 2019

    1. Fischer, R., Padutsch, T., Bracchi-Ricard, V., Murphy, K. L., Martinez, George. F., Delguercio, N., Elmer, N., Sendetski, M., Diem, R., Eisel, U. L. M., Smeyne, R. J., Kontermann, R. E., Pfizenmaier, K., & Bethea, J. R. (2019). Exogenous activation of tumor necrosis factor receptor 2 promotes recovery from sensory and motor disease in a model of multiple sclerosis. Brain, Behavior, and Immunity. https://doi.org/10.1016/j.bbi.2019.06.021
    2. Lieb, W. S., Lungu, C., Tamas, R., Berreth, H., Rathert, P., Storz, P., Olayioye, M. A., & Hausser, A. (2019). The GEF‐H1/PKD3 signaling pathway promotes the maintenance of triple negative breast cancer stem cells. International Journal of Cancer, ijc. https://doi.org/10.1002/ijc.32798
    3. Noonan, J. J., Jarzabek, M., Lincoln, F. A., Cavanagh, B. L., Pariag, A. R., Juric, V., Young, L. S., Ligon, K. L., Jahns, H., Zheleva, D., Prehn, J. H. M., Rehm, M., Byrne, A. T., & Murphy, B. M. (2019). Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma. Cancers (Basel), 11, Article 12. https://doi.org/10.3390/cancers11122005
    4. Beha, N., Harder, M., Ring, S., Kontermann, R. E., & Müller, D. (2019). IL-15-based trifunctional antibody-fusion proteins with costimulatory TNF-superfamily ligands in the single-chain format for cancer immunotherapy. Molecular Cancer Therapeutics, molcanther. https://doi.org/10.1158/1535-7163.MCT-18-1204
    5. Schrade, A., Bujotzek, A., Spick, C., Wagner, M., Goerl, J., Wezler, X., Georges, G., Kontermann, R. E., & Brinkmann, U. (2019). Back-To-Germline (B2G) Procedure for Antibody Devolution. Antibodies, 8, Article 3. https://doi.org/10.3390/antib8030045
    6. Kleih, M., Böpple, K., Dong, M., Gaißler, A., Heine, S., Olayioye, M. A., Aulitzky, W. E., & Essmann, F. (2019). Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell Death & Disease, 10, Article 11. https://doi.org/10.1038/s41419-019-2081-4
    7. Fischer, R., Sendetski, M., Del Rivero, T., Martinez, G. F., Bracchi-Ricard, V., Swanson, K. A., Pruzinsky, E. K., Delguercio, N., Rosalino, M. J., Padutsch, T., Kontermann, R. E., Pfizenmaier, K., & Bethea, J. R. (2019). TNFR2 promotes Treg-mediated recovery from neuropathic pain across sexes. Proceedings of the National Academy of Sciences of the United States of America, 116, Article 34. https://doi.org/10.1073/pnas.1902091116
    8. von Blume, J., & Hausser, A. (2019). Lipid‐dependent coupling of secretory cargo sorting and trafficking at the trans‐Golgi network. FEBS Letters, 1873–3468. https://doi.org/10.1002/1873-3468.13552
    9. Tsur, N., Kogan, Y., Rehm, M., & Agur, Z. (2019). Response of Patients with Melanoma to Immune Checkpoint Blockade – Insights Gleaned from Analysis of a New Mathematical Mechanistic Model. Journal of Theoretical Biology, 110033. https://doi.org/10.1016/J.JTBI.2019.110033
    10. Salvucci, M., Rahman, A., Resler, A. J., Udupi, G. M., McNamara, D. A., Kay, E. W., Laurent-Puig, P., Longley, D. B., Johnston, P. G., Lawler, M., Wilson, R., Salto-Tellez, M., Van Schaeybroeck, S., Rafferty, M., Gallagher, W. M., Rehm, M., & Prehn, J. H. M. (2019). A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic. JCO Clinical Cancer Informatics, Article 3. https://doi.org/10.1200/CCI.18.00056
    11. Skoko, J., Rožanc, J., Charles, E. M., Alexopoulos, L. G., & Rehm, M. (2019). Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma. BMC Cell Biology, 19, Article 1. https://doi.org/10.1186/s12860-018-0180-1
    12. Noll, B., Benz, D., Frey, Y., Meyer, F., Lauinger, M., Eisler, S. A., Schmid, S., Hordijk, P. L., & Olayioye, M. A. (2019). DLC3 suppresses MT1-MMP-dependent matrix degradation by controlling RhoB and actin remodeling at endosomal membranes. Journal of Cell Science, jcs. https://doi.org/10.1242/jcs.223172
    13. Seifert, O., Rau, A., Beha, N., Richter, F., & Kontermann, R. E. (2019). Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules. mAbs, 19420862. https://doi.org/10.1080/19420862.2019.1603024
    14. Padutsch, T., Maksim, S., Huber, C., Peters, N., Pfizenmaier, K., Bethea, J. R., Kontermann, R. E., & Fischer, R. (2019). Superior Treg-expanding properties of a novel dual-acting cytokine fusion protein. Frontiers in Pharmacology, 10, 1490. https://doi.org/10.3389/FPHAR.2019.01490
    15. Podder, B., Guttà, C., Rožanc, J., Gerlach, E., Feoktistova, M., Panayotova-Dimitrova, D., Alexopoulos, L. G., Leverkus, M., & Rehm, M. (2019). TAK1 suppresses RIPK1-dependent cell death and is associated with disease progression in melanoma. Cell Death & Differentiation, 1. https://doi.org/10.1038/s41418-019-0315-8
    16. Richter, F., Seifert, O., Herrmann, A., Pfizenmaier, K., & Kontermann, R. E. (2019). Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc. mAbs, 1–13. https://doi.org/10.1080/19420862.2019.1596512

  9. 2018

    1. Crawford, N., Salvucci, M., Hellwig, C. T., Lincoln, F. A., Mooney, R. E., O’Connor, C. L., Prehn, J. H., Longley, D. B., & Rehm, M. (2018). Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711. Cell Death & Differentiation. https://doi.org/10.1038/s41418-018-0082-y
    2. Del Mistro, G., Lucarelli, P., Müller, I., De Landtsheer, S., Zinoveva, A., Hutt, M., Siegemund, M., Kontermann, R. E., Beissert, S., Sauter, T., & Kulms, D. (2018). Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma. Npj Systems Biology and Applications, 4, Article 1. https://doi.org/10.1038/s41540-018-0075-y
    3. Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., Annicchiarico-Petruzzelli, M., Antonov, A. V., Arama, E., Baehrecke, E. H., Barlev, N. A., Bazan, N. G., Bernassola, F., Bertrand, M. J. M., Bianchi, K., et al. (2018). Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death & Differentiation. https://doi.org/10.1038/s41418-017-0012-4
    4. Hutt, M., Fellermeier-Kopf, S., Seifert, O., Schmitt, L. C., Pfizenmaier, K., & Kontermann, R. E. (2018). Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells. Oncotarget, 9, Article 13. https://doi.org/10.18632/oncotarget.24379
    5. Almanza, A., Carlesso, A., Chintha, C., Creedican, S., Doultsinos, D., Leuzzi, B., Luís, A., McCarthy, N., Montibeller, L., More, S., Papaioannou, A., Püschel, F., Sassano, M. L., Skoko, J., Agostinis, P., de Belleroche, J., Eriksson, L. A., Fulda, S., Gorman, A. M., et al. (2018). Endoplasmic Reticulum Stress signalling - from basic mechanisms to clinical applications. The FEBS Journal. https://doi.org/10.1111/febs.14608
    6. Lincoln, F. A., Imig, D., Boccellato, C., Juric, V., Noonan, J., Kontermann, R. E., Allgöwer, F., Murphy, B. M., & Rehm, M. (2018). Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism. Cell Death & Disease, 9, Article 11. https://doi.org/10.1038/s41419-018-1160-2
    7. Eisler, S. A., Curado, F., Link, G., Schulz, S., Noack, M., Steinke, M., Olayioye, M. A., & Hausser, A. (2018). A Rho signaling network links microtubules to PKD controlled carrier transport to focal adhesions. eLife, 7. https://doi.org/10.7554/eLife.35907
    8. Carberry, S., D’Orsi, B., Monsefi, N., Salvucci, M., Bacon, O., Fay, J., Rehm, M., McNamara, D., Kay, E. W., & Prehn, J. M. H. (2018). The BAX/BAK-like protein BOK is a prognostic marker in colorectal cancer. Cell Death & Disease, 9, Article 2. https://doi.org/10.1038/s41419-017-0140-2
    9. Fellermeier-Kopf, S., Gieseke, F., Sahin, U., Müller, D., Pfizenmaier, K., & Kontermann, R. E. (2018). Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans. OncoImmunology, 7, Article 9. https://doi.org/10.1080/2162402X.2018.1471442
    10. Apweiler, R., Beissbarth, T., Berthold, M. R., Blüthgen, N., Burmeister, Y., Dammann, O., Deutsch, A., Feuerhake, F., Franke, A., Hasenauer, J., Hoffmann, S., Höfer, T., Jansen, P. L., Kaderali, L., Klingmüller, U., Koch, I., Kohlbacher, O., Kuepfer, L., Lammert, F., et al. (2018). Whither systems medicine? Experimental &Amp; Molecular Medicine, 50, e453––. http://dx.doi.org/10.1038/emm.2017.290
    11. Danish, L., Imig, D., Allgöwer, F., Scheurich, P., & Pollak, N. (2018). Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps. Plos One, 13, Article 6. https://doi.org/10.1371/journal.pone.0198203
    12. Jensch, A., Frey, Y., Bitschar, K., Weber, P., Schmid, S., Hausser, A., Olayioye, M. A., & Radde, N. E. (2018). The tumor suppressor protein DLC1 maintains protein kinase D activity and Golgi secretory function. Journal of Biological Chemistry, jbc. https://doi.org/10.1074/jbc.RA118.003787
    13. Tansi, F. L., Rüger, R., Kollmeier, A. M., Rabenhold, M., Steiniger, F., Kontermann, R. E., Teichgraeber, U. K., Fahr, A., & Hilger, I. (2018). Endoglin based in vivo near-infrared fluorescence imaging of tumor models in mice using activatable liposomes. Biochimica et Biophysica Acta (BBA) - General Subjects. https://doi.org/10.1016/j.bbagen.2018.03.012
    14. Richter, F., Zettlitz, K. A., Seifert, O., Herrmann, A., Scheurich, P., Pfizenmaier, K., & Kontermann, R. E. (2018). Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity. mAbs, 19420862. https://doi.org/10.1080/19420862.2018.1524664
    15. Siegemund, M., Schneider, F., Hutt, M., Seifert, O., Müller, I., Kulms, D., Pfizenmaier, K., & Kontermann, R. E. (2018). IgG-single-chain TRAIL fusion proteins for tumour therapy. Scientific Reports, 8, Article 1. https://doi.org/10.1038/s41598-018-24450-8
    16. Rožanc, J., Sakellaropoulos, T., Antoranz, A., Guttà, C., Podder, B., Vetma, V., Rufo, N., Agostinis, P., Pliaka, V., Sauter, T., Kulms, D., Rehm, M., & Alexopoulos, L. (2018). Phosphoprotein patterns predict trametinib responsiveness and optimal trametinib sensitisation strategies in melanoma. Cell Death & Differentiation, 1. https://doi.org/10.1038/s41418-018-0210-8
    17. Chen, M., Urs, M. J., Sánchez-González, I., Olayioye, M. A., Herde, M., & Witte, C.-P. (2018). m6A RNA Degradation Products are Catabolized by an Evolutionarily Conserved N6-methyl-AMP Deaminase in Plant and Mammalian Cells. The Plant Cell, tpc. https://doi.org/10.1105/tpc.18.00236
    18. Fischer, R., Proske, M., Duffey, M., Stangl, H., Martinez, G. F., Peters, N., Kraske, A., Straub, R. H., Bethea, J. R., Kontermann, R. E., & Pfizenmaier, K. (2018). Selective activation of tumor necrosis factor receptor 2 induces anti-inflammatory responses and alleviates experimental arthritis. Arthritis & Rheumatology. https://doi.org/10.1002/art.40413
    19. Hantusch, A., Rehm, M., & Brunner, T. (2018). Counting on Death - Quantitative aspects of Bcl-2 family regulation. The FEBS Journal. https://doi.org/10.1111/febs.14516
    20. Satta, A., Mezzanzanica, D., Caroli, F., Frigerio, B., Nicola, M. D., Kontermann, R. E., Iacovelli, F., Desideri, A., Anichini, A., Canevari, S., Gianni, A. M., & Figini, M. (2018). Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. mAbs, 19420862. https://doi.org/10.1080/19420862.2018.1494105
    21. Puerto-Camacho, P., Amaral, A. T., Lamhamedi-Cherradi, S.-E., Menegaz, B. A., Castillo-Ecija, H., Ordóñez, J. L., Dominguez-Hormaetxe, S., Jordan-Perez, C., Diaz-Martin, J., Romero-Pérez, L., Lopez-Alvarez, M., Civantos-Jubera, G., Robles-Frias, M. J., Biscuola, M., Ferrer, C., Mora, J., Cuglievan, B., Schadler, K. L., Seifert, O., et al. (2018). Preclinical efficacy of endoglin-targeting antibody-drug conjugates for the treatment of Ewing sarcoma. Clinical Cancer Research, clincanres. https://doi.org/10.1158/1078-0432.CCR-18-0936
    22. Hantusch, A., Das, K. K., García-Sáez, A. J., Brunner, T., & Rehm, M. (2018). Bax retrotranslocation potentiates Bcl-xL’s antiapoptotic activity and is essential for switch-like transitions between MOMP competency and resistance. Cell Death & Disease, 9, Article 4. https://doi.org/10.1038/s41419-018-0464-6
    23. Williams, S. K., Fairless, R., Maier, O., Liermann, P. C., Pichi, K., Fischer, R., Eisel, U. L. M., Kontermann, R., Herrmann, A., Weksler, B., Romero, N., Couraud, P.-O., Pfizenmaier, K., & Diem, R. (2018). Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis. Scientific Reports, 8, Article 1. https://doi.org/10.1038/s41598-018-31957-7

  10. 2017

    1. Hausser, A., & Schlett, K. (2017). Coordination of AMPA receptor trafficking by Rab GTPases. Small GTPases, 1–14. https://doi.org/10.1080/21541248.2017.1337546
    2. Pieper, L. A., Strotbek, M., Wenger, T., Olayioye, M. A., & Hausser, A. (2017). ATF6β-based fine-tuning of the unfolded protein response enhances therapeutic antibody productivity of Chinese hamster ovary cells. Biotechnology and Bioengineering, 114, Article 6. https://doi.org/10.1002/bit.26263
    3. Capasso, S., Sticco, L., Rizzo, R., Pirozzi, M., Russo, D., Dathan, N. A., Campelo, F., van Galen, J., Hölttä‐Vuori, M., Turacchio, G., Hausser, A., Malhotra, V., Riezman, I., Riezman, H., Ikonen, E., Luberto, C., Parashuraman, S., Luini, A., & D’Angelo, G. (2017). Sphingolipid metabolic flow controls phosphoinositide turnover at the \textlessi\textgreatertrans\textless/i\textgreater ‐Golgi network. The EMBO Journal, 36, Article 12. https://doi.org/10.15252/embj.201696048
    4. Schmitt, L. C., Rau, A., Seifert, O., Honer, J., Hutt, M., Schmid, S., Zantow, J., Hust, M., Dübel, S., Olayioye, M. A., & Kontermann, R. E. (2017). Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV. mAbs, 9, Article 5. https://doi.org/10.1080/19420862.2017.1319023
    5. Kuritz, K., Stöhr, D., Pollak, N., & Allgöwer, F. (2017). On the relationship between cell cycle analysis with ergodic principles and age-structured cell population models. Journal of Theoretical Biology, 414, 91–102. https://doi.org/10.1016/j.jtbi.2016.11.024
    6. Fischer, R., Marsal, J., Guttà, C., Eisler, S. A., Peters, N., Bethea, J. R., Pfizenmaier, K., & Kontermann, R. E. (2017). Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2. Scientific Reports, 7, Article 1. https://doi.org/10.1038/s41598-017-06993-4
    7. Brinkmann, U., & Kontermann, R. E. (2017). The making of bispecific antibodies. mAbs, 9, Article 2. https://doi.org/10.1080/19420862.2016.1268307
    8. Schröder, P., Wagner, A., Stöhr, D., Rehm, M., & Ehlers, W. (2017). Data-driven simulation of metastatic processes within brain tissue. Pamm, 17, Article 1. https://doi.org/10.1002/pamm.201710080
    9. Pieper, L. A., Strotbek, M., Wenger, T., Gamer, M., Olayioye, M. A., & Hausser, A. (2017). Secretory pathway optimization of CHO producer cells by co-engineering of the mitosRNA-1978 target genes CerS2 and Tbc1D20. Metabolic Engineering, 40, 69–79. https://doi.org/10.1016/j.ymben.2017.01.003
    10. Vetma, V., Rozanc, J., Charles, E. M., Hellwig, C. T., Alexopoulos, L. G., & Rehm, M. (2017). Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 25, Article 9. https://doi.org/10.3727/096504017x14897145996933
    11. Hantusch, A., Brunner, T., Frickey, T., & Rehm, M. (2017). Bcl-2-Ome-a database and interactive web service for dissecting the Bcl-2 interactome. Cell Death and Differentiation, 24, Article 1. https://doi.org/10.1038/cdd.2016.129
    12. Hutt, M., Marquardt, L., Seifert, O., Siegemund, M., Müller, I., Kulms, D., Pfizenmaier, K., & Kontermann, R. E. (2017). Superior properties of Fc-comprising scTRAIL fusion proteins. Molecular Cancer Therapeutics, 16, Article 12. https://doi.org/10.1158/1535-7163.MCT-17-0551
    13. Salvucci, M., Urstle, M. L., Morgan, C., Curry, S., Cremona, M., Lindner, A. U., Bacon, O., Resler, A. J., Murphy, A. C., O’Byrne, R., Flanagan, L., Dasgupta, S., Rice, N., Pilati, C., Zink, E., Scholler, L. M., Toomey, S., Lawler, M., Johnston, P. G., et al. (2017). A stepwise integrated approach to personalized risk predictions in stage III colorectal cancer. Clinical Cancer Research, 23, Article 5. https://doi.org/10.1158/1078-0432.CCR-16-1084
    14. Strotbek, M., Schmid, S., Sánchez-González, I., Boerries, M., Busch, H., & Olayioye, M. A. (2017). miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer. International Journal of Cancer, 140, Article 10. https://doi.org/10.1002/ijc.30661
    15. Lakner, P. H., Monaghan, M. G., Möller, Y., Olayioye, M. A., & Schenke-Layland, K. (2017). Applying phasor approach analysis of multiphoton FLIM measurements to probe the metabolic activity of three-dimensional in vitro cell culture models. Scientific Reports, 7, 42730. https://doi.org/10.1038/srep42730
    16. Sapski, S., Beha, N., Kontermann, R., & Müller, D. (2017). Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors. OncoImmunology, 6, Article 12. https://doi.org/10.1080/2162402X.2017.1361594

  11. 2016

    1. Hendrick, J., & Olayioye, M. A. (2016). Spatial Rho regulation: Molecular mechanisms controlling the GAP protein DLC3. Small GTPases, 1–7. https://doi.org/10.1080/21541248.2016.1260673
    2. Dong, Y., Fischer, R., Naudé, P. J. W., Maier, O., Nyakas, C., Duffey, M., Van der Zee, E. A., Dekens, D., Douwenga, W., Herrmann, A., Guenzi, E., Kontermann, R. E., Pfizenmaier, K., & Eisel, U. L. M. (2016). Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration. Proceedings of the National Academy of Sciences, 113, Article 43. https://doi.org/10.1073/pnas.1605195113
    3. Fellermeier, S., Beha, N., Meyer, J. E., Ring, S., Bader, S., Kontermann, R. E., & Müller, D. (2016). Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format. OncoImmunology, 5, Article 11. https://doi.org/10.1080/2162402X.2016.1238540
    4. Kontermann, R. E. (2016). Half-life extended biotherapeutics. Expert Opinion on Biological Therapy, 16, Article 7. https://doi.org/10.1517/14712598.2016.1165661
    5. Siegemund, M., Seifert, O., Zarani, M., Dzinić, T., De Leo, V., Göttsch, D., Münkel, S., Hutt, M., Pfizenmaier, K., & Kontermann, R. E. (2016). An optimized antibody-single-chain TRAIL fusion protein for cancer therapy. mAbs, 8, Article 5. https://doi.org/10.1080/19420862.2016.1172163
    6. Möller, Y., Morkel, M., Schmid, J., Beyes, S., Hendrick, J., Strotbek, M., Riemer, P., Schmid, S., Schmitt, L. C., Kontermann, R., Mürdter, T., Schwab, M., Sers, C., & Olayioye, M. a. (2016). Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling. Oncotarget, 7, Article 33. https://doi.org/10.18632/oncotarget.10658
    7. Hellwig, C. T., Ludwig-Galezowska, A. H., & Rehm, M. (2016). FRET-Based Measurement of Apoptotic Caspase Activities by High-Throughput Screening Flow Cytometry. In P. M. Muganda (Ed.), Apoptosis Methods in Toxicology (pp. 109–130). Springer New York. https://doi.org/10.1007/978-1-4939-3588-8_7
    8. Hendrick, J., Franz-Wachtel, M., Moeller, Y., Schmid, S., Macek, B., & Olayioye, M. A. (2016). The polarity protein Scribble positions DLC3 at adherens junctions to regulate Rho signaling. Journal of Cell Science, 129, Article 19. https://doi.org/10.1242/jcs.190074
    9. Weyhenmeyer, B. C., Noonan, J., Würstle, M. L., Lincoln, F. A., Johnston, G., Rehm, M., & Murphy, B. M. (2016). Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide. Oncotarget, 7, Article 38. https://doi.org/10.18632/oncotarget.10973
    10. Szíber, Z., Liliom, H., Morales, C. O. O., Ignácz, A., Rátkai, A. E., Ellwanger, K., Link, G., Szűcs, A., Hausser, A., & Schlett, K. (2016). Ras and Rab interactor 1 controls neuronal plasticity by coordinating dendritic filopodial motility and AMPA receptor turnover. Molecular Biology of the Cell, 28, Article 2. https://doi.org/10.1091/mbc.E16-07-0526
    11. Tansi, F. L., Rüger, R., Böhm, C., Kontermann, R. E., Teichgraeber, U. K., Fahr, A., & Hilger, I. (2016). Potential of activatable FAP-targeting immunoliposomes in intraoperative imaging of spontaneous metastases. Biomaterials, 88, 70–82. https://doi.org/10.1016/j.biomaterials.2016.02.028
    12. Unverdorben, F., Richter, F., Hutt, M., Seifert, O., Malinge, P., Fischer, N., & Kontermann, R. E. (2016). Pharmacokinetic properties of IgG and various Fc fusion proteins in mice. mAbs, 8, Article 1. https://doi.org/10.1080/19420862.2015.1113360
    13. Kälble, F., Damaske, J., Heide, D., Arnold, I., Richter, F., Maier, O., Eisel, U., Scheurich, P., Pfizenmaier, K., Zeier, M., Schwenger, V., & Ranzinger, J. (2016). Selective blocking of TNF receptor 1 attenuates peritoneal dialysis fluid induced inflammation of the peritoneum in mice. PLoS ONE, 11, Article 10. https://doi.org/10.1371/journal.pone.0163314
    14. Fiedler, A., Raeth, S., Theis, F. J., Hausser, A., & Hasenauer, J. (2016). Tailored parameter optimization methods for ordinary differential equation models with steady-state constraints. BMC Systems Biology, 10, Article 1. https://doi.org/10.1186/s12918-016-0319-7

  12. 2015

    1. Kang, B., Okwieka, P., Schöttler, S., Seifert, O., Kontermann, R. E., Pfizenmaier, K., Musyanovych, A., Meyer, R., Diken, M., Sahin, U., Mailänder, V., Wurm, F. R., & Landfester, K. (2015). Tailoring the stealth properties of biocompatible polysaccharide nanocontainers. Biomaterials, 49, 125–134. https://doi.org/10.1016/j.biomaterials.2015.01.042
    2. Fernández-Ulibarri, I., Hammer, K., Arndt, M. A. E., Kaufmann, J. K., Dorer, D., Engelhardt, S., Kontermann, R. E., Hess, J., Allgayer, H., Krauss, J., & Nettelbeck, D. M. (2015). Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity. International Journal of Cancer, 136, Article 9. https://doi.org/10.1002/ijc.29258
    3. Weber, P., Hornjik, M., Olayioye, M. A., Hausser, A., & Radde, N. E. (2015). A computational model of PKD and CERT interactions at the trans-Golgi network of mammalian cells. BMC Systems Biology, 9, Article 1. https://doi.org/10.1186/s12918-015-0147-1
    4. Wortzel, I., Hanoch, T., Porat, Z., Hausser, A., & Seger, R. (2015). Mitotic Golgi translocation of ERK1c is mediated by PI4KIIIβ/14-3-3γ shuttling complex. Journal of Cell Science, 204, Article 22. https://doi.org/10.1242/jcs.170910
    5. Bencsik, N., Szíber, Z., Liliom, H., Tárnok, K., Borbély, S., Gulyás, M., Rátkai, A., Szucs, A., Hazai-Novák, D., Ellwanger, K., Rácz, B., Pfizenmaier, K., Hausser, A., & Schlett, K. (2015). Protein kinase D promotes plasticity-induced F-actin stabilization in dendritic spines and regulates memory formation. Journal of Cell Biology, 210, Article 5. https://doi.org/10.1083/jcb.201501114
    6. Kontermann, R. E., & Brinkmann, U. (2015). Bispecific antibodies. Drug Discovery Today, 20, Article 7. https://doi.org/10.1016/j.drudis.2015.02.008
    7. Braun, A. C., Hendrick, J., Eisler, S. A., Schmid, S., Hausser, A., & Olayioye, M. A. (2015). The Rho-specific GAP protein DLC3 coordinates endocytic membrane trafficking. Journal of Cell Science, 128, Article 7. https://doi.org/10.1242/jcs.163857
    8. Fischer, R., & Maier, O. (2015). Interrelation of oxidative stress and inflammation in neurodegenerative disease: Role of TNF. Oxidative Medicine and Cellular Longevity, 2015, 1–18. https://doi.org/10.1155/2015/610813
    9. Müller, D. (2015). Antibody fusions with immunomodulatory proteins for cancer therapy. Pharmacology and Therapeutics, 154, 57–66. https://doi.org/10.1016/j.pharmthera.2015.07.001
    10. Schuster, L., Seifert, O., Vollmer, S., Kontermann, R. E., Schlosshauer, B., & Hartmann, H. (2015). Immunoliposomes for Targeted Delivery of an Antifibrotic Drug. Molecular Pharmaceutics, 12, Article 9. https://doi.org/10.1021/acs.molpharmaceut.5b00012
    11. Unverdorben, F., Hutt, M., Seifert, O., & Kontermann, R. E. (2015). A fab-selective immunoglobulin-binding domain from streptococcal protein G with improved half-life extension properties. PLoS ONE, 10, Article 10. https://doi.org/10.1371/journal.pone.0139838
    12. Fischer, R., Kontermann, R., & Maier, O. (2015). Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy. Antibodies, 4, Article 1. https://doi.org/10.3390/antib4010048
    13. Tárnok, K., Gulyás, M., Bencsik, N., Ferenc, K., Pfizenmaier, K., Hausser, A., & Schlett, K. (2015). A new tool for the quantitative analysis of dendritic filopodial motility. Cytometry Part A, 87, Article 1. https://doi.org/10.1002/cyto.a.22569
    14. Rabenhold, M., Steiniger, F., Fahr, A., Kontermann, R. E., & Rüger, R. (2015). Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously. Journal of Controlled Release, 201, 56–67. https://doi.org/10.1016/j.jconrel.2015.01.022
    15. Herr, R., Köhler, M., Andrlová, H., Weinberg, F., Möller, Y., Halbach, S., Lutz, L., Mastroianni, J., Klose, M., Bittermann, N., Kowar, S., Zeiser, R., Olayioye, M. A., Lassmann, S., Busch, H., Boerries, M., & Brummer, T. (2015). B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells. Cancer Research, 75, Article 1. https://doi.org/10.1158/0008-5472.CAN-13-3686
    16. Braun, A. C., & Olayioye, M. A. (2015). Rho regulation: DLC proteins in space and time. Cellular Signalling, 27, Article 8. https://doi.org/10.1016/j.cellsig.2015.04.003

  13. 2014

    1. Lindner, R., Moosmann, A., Dietrich, A., Böttinger, H., Kontermann, R., & Siemann-Herzberg, M. (2014). Process development of periplasmatically produced single chain fragment variable against epidermal growth factor receptor in Escherichia coli. Journal of Biotechnology, 192, 136–145. https://doi.org/10.1016/j.jbiotec.2014.10.003
    2. Fischer, R., Wajant, H., Kontermann, R., Pfizenmaier, K., & Maier, O. (2014). Astrocyte-specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor. Glia, 62, Article 2. https://doi.org/10.1002/glia.22605
    3. Jaiswal, M., Dvorsky, R., Amin, E., Risse, S. L., Fansa, E. K., Zhang, S. C., Taha, M. S., Gauhar, A. R., Nakhaei-Rad, S., Kordes, C., Koessmeier, K. T., Cirstea, I. C., Olayioye, M. A., Häussinger, D., & Ahmadian, M. R. (2014). Functional cross-talk between ras and rho pathways: A ras-specific gtpase-activating protein (p120RasGAP) competitively inhibits the rhogap activity of deleted in liver cancer (DLC) tumor suppressor by masking the catalytic arginine finger. Journal of Biological Chemistry, 289, Article 10. https://doi.org/10.1074/jbc.M113.527655
    4. Barras, D., Chevalier, N., Zoete, V., Dempsey, R., Lapouge, K., Olayioye, M. A., Michielin, O., & Widmann, C. (2014). A WXW Motif Is Required for the Anticancer Activity of the TAT-RasGAP317–326 Peptide. Journal of Biological Chemistry, 289, Article 34. https://doi.org/10.1074/jbc.M114.576272
    5. Seifert, O., Pollak, N., Nusser, A., Steiniger, F., Rüger, R., Pfizenmaier, K., & Kontermann, R. E. (2014). Immuno-LipoTRAIL: Targeted delivery of TRAIL-functionalized liposomal nanoparticles. Bioconjugate Chemistry, 25, Article 5. https://doi.org/10.1021/bc400517j
    6. Siegemund, M., Richter, F., Seifert, O., Unverdorben, F., & Kontermann, R. E. (2014). Expression and Purification of Recombinant Antibody Formats and Antibody Fusion Proteins. In Methods in molecular biology (Clifton, N.J.) (Vol. 1131, pp. 273–295). https://doi.org/10.1007/978-1-62703-992-5_18
    7. Diebolder, P., Keller, A., Haase, S., Schlegelmilch, A., Kiefer, J. D., Karimi, T., Weber, T., Moldenhauer, G., Kehm, R., Eis-Hübinger, A. M., Jäger, D., Federspil, P. A., Herold-Mende, C., Dyckhoff, G., Kontermann, R. E., Arndt, M. A., & Krauss, J. (2014). Generation of “LYmph Node Derived Antibody Libraries” (LYNDAL) for selecting fully human antibody fragments with therapeutic potential. mAbs, 6, Article 1. https://doi.org/10.4161/mabs.27236
    8. Moosmann, A., Müller, E., & Böttinger, H. (2014). Purification of PEGylated Proteins, with the example of PEGylated lysozyme and PEGylated scFv. Methods in Molecular Biology, 1129, 527–538. https://doi.org/10.1007/978-1-62703-977-2_37
    9. Weidle, U. H., Kontermann, R. E., & Brinkmann, U. (2014). Tumor-antigen-binding bispecific antibodies for cancer treatment. Seminars in Oncology, 41, Article 5. https://doi.org/10.1053/j.seminoncol.2014.08.004
    10. Rüger, R., Tansi, F. L., Rabenhold, M., Steiniger, F., Kontermann, R. E., Fahr, A., & Hilger, I. (2014). In vivo near-infrared fluorescence imaging of FAP-expressing tumors with activatable FAP-targeted, single-chain Fv-immunoliposomes. Journal of Controlled Release, 186, 1–10. https://doi.org/10.1016/j.jconrel.2014.04.050
    11. Kermer, V., Hornig, N., Harder, M., Bondarieva, A., Kontermann, R. E., & Muller, D. (2014). Combining Antibody-Directed Presentation of IL-15 and 4-1BBL in a Trifunctional Fusion Protein for Cancer Immunotherapy. Molecular Cancer Therapeutics, 13, Article 1. https://doi.org/10.1158/1535-7163.MCT-13-0282
    12. Huck, B., Duss, S., Hausser, A., & Olayioye, M. A. (2014). Elevated protein kinase D3 (PKD3) expression supports proliferation of Triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation. Journal of Biological Chemistry, 289, Article 6. https://doi.org/10.1074/jbc.M113.502633
    13. Neumann, S., Hasenauer, J., Pollak, N., & Scheurich, P. (2014). Dominant negative effects of tumor necrosis factor (tnf)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by Formation of heteromeric complexes. Journal of Biological Chemistry, 289, Article 23. https://doi.org/10.1074/jbc.M114.559468
    14. Oesterreich, B., Lorenz, B., Schmitter, T., Kontermann, R., Zenn, M., Zimmermann, B., Haake, M., Lorenz, U., & Ohlsen, K. (2014). Characterization of the biological anti-staphylococcal functionality of hUK-66 IgG1, ahumanized monoclonal antibody as substantial component for an immunotherapeutic approach. Human Vaccines and Immunotherapeutics, 10, Article 4. https://doi.org/10.4161/hv.27692
    15. Seifert, O., Plappert, A., Fellermeier, S., Siegemund, M., Pfizenmaier, K., & Kontermann, R. E. (2014). Tetravalent Antibody-scTRAIL Fusion Proteins with Improved Properties. Molecular Cancer Therapeutics, 13, Article 1. https://doi.org/10.1158/1535-7163.MCT-13-0396
    16. Möller, Y., Siegemund, M., Beyes, S., Herr, R., Lecis, D., Delia, D., Kontermann, R., Brummer, T., Pfizenmaier, K., & Olayioye, M. A. (2014). EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells. PLoS ONE, 9, Article 9. https://doi.org/10.1371/journal.pone.0107165
    17. Bischoff, A., Huck, B., Keller, B., Strotbek, M., Schmid, S., Boerries, M., Busch, H., Müller, D., & Olayioye, M. A. (2014). MiR149 functions as a tumor suppressor by controlling breast epithelial cell migration and invasion. Cancer Research, 74, Article 18. https://doi.org/10.1158/0008-5472.CAN-13-3319
    18. Kiesgen, S., Liebers, N., Cremer, M., Arnold, U., Weber, T., Keller, A., Herold-Mende, C., Dyckhoff, G., Jäger, D., Kontermann, R. E., Arndt, M. A. E., Krauss, J., & Wu, A. (2014). A fusogenic dengue virus-derived peptide enhances antitumor efficacy of an antibody-ribonuclease fusion protein targeting the EGF receptor. Protein Engineering, Design and Selection, 27, Article 10. https://doi.org/10.1093/protein/gzu040
    19. Williams, S. K., Maier, O., Fischer, R., Fairless, R., Hochmeister, S., Stojic, A., Pick, L., Haar, D., Musiol, S., Storch, M. K., Pfizenmaier, K., & Diem, R. (2014). Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis. PLoS ONE, 9, Article 2. https://doi.org/10.1371/journal.pone.0090117
    20. Wille, C., Köhler, C., Armacki, M., Jamali, A., Gössele, U., Pfizenmaier, K., Seufferlein, T., & Eiseler, T. (2014). Protein kinase D2 induces invasion of pancreatic cancer cells by regulating matrix metalloproteinases. Molecular Biology of the Cell, 25, Article 3. https://doi.org/10.1091/mbc.E13-06-0334
    21. Konrath, F., Witt, J., Sauter, T., & Kulms, D. (2014). Identification of New IκBα Complexes by an Iterative Experimental and Mathematical Modeling Approach. PLoS Computational Biology, 10, Article 3. https://doi.org/10.1371/journal.pcbi.1003528
    22. Raeth, S., Sacchetti, B., Siegel, G., Mau-Holzmann, U. a., Hansmann, J., Vacun, G., Hauk, T. G., Pfizenmaier, K., & Hausser, A. (2014). A mouse bone marrow stromal cell line with skeletal stem cell characteristics to study osteogenesis in vitro and in vivo. Stem Cells and Development, 23, Article 10. https://doi.org/10.1089/scd.2013.0367

  14. 2013

    1. Wajant, H., Gerspach, J., & Pfizenmaier, K. (2013). Engineering death receptor ligands for cancer therapy. Cancer Letters, 332, Article 2. https://doi.org/10.1016/j.canlet.2010.12.019
    2. Richter, F., Liebig, T., Guenzi, E., Herrmann, A., Scheurich, P., Pfizenmaier, K., & Kontermann, R. E. (2013). Antagonistic TNF receptor one-specific antibody (ATROSAB): Receptor binding and in vitro bioactivity. PLoS ONE, 8, Article 8. https://doi.org/10.1371/journal.pone.0072156
    3. Maier, O., Fischer, R., Agresti, C., & Pfizenmaier, K. (2013). TNF receptor 2 protects oligodendrocyte progenitor cells against oxidative stress. Biochemical and Biophysical Research Communications, 440, Article 2. https://doi.org/10.1016/j.bbrc.2013.09.083
    4. Hornig, N., Reinhardt, K., Kermer, V., Kontermann, R. E., & Müller, D. (2013). Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. Cancer Immunology, Immunotherapy, 62, Article 8. https://doi.org/10.1007/s00262-013-1441-7
    5. Kienzle, C., Eisler, S. A., Villeneuve, J., Brummer, T., Olayioye, M. A., & Hausser, A. (2013). PKD controls mitotic Golgi complex fragmentation through a Raf-MEK1 pathway. Molecular Biology of the Cell, 24, Article 3. https://doi.org/10.1091/mbc.E12-03-0198
    6. Olayioye, M. A., Barisic, S., & Hausser, A. (2013). Multi-level control of actin dynamics by protein kinase D. Cellular Signalling, 25, Article 9. https://doi.org/10.1016/j.cellsig.2013.04.010
    7. Wahl, K., Siegemund, M., Lehner, F., Vondran, F., Nüssler, A., Länger, F., Krech, T., Kontermann, R., Manns, M. P., Schulze-Osthoff, K., Pfizenmaier, K., & Bantel, H. (2013). Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib. Hepatology, 57, Article 2. https://doi.org/10.1002/hep.26082
    8. Berger, V., Richter, F., Zettlitz, K., Unverdorben, F., Scheurich, P., Herrmann, A., Pfizenmaier, K., & Kontermann, R. E. (2013). An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action. Protein Engineering, Design and Selection, 26, Article 10. https://doi.org/10.1093/protein/gzt044
    9. Ellwanger, K., & Hausser, A. (2013). Physiological functions of protein kinase D in vivo. IUBMB Life, 65, Article 2. https://doi.org/10.1002/iub.1116
    10. Kakarla, S., Chow, K. K. H., Mata, M., Shaffer, D. R., Song, X. T., Wu, M. F., Liu, H., Wang, L. L., Rowley, D. R., Pfizenmaier, K., & Gottschalk, S. (2013). Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Molecular Therapy, 21, Article 8. https://doi.org/10.1038/mt.2013.110
    11. Vörsmann, H., Groeber, F., Walles, H., Busch, S., Beissert, S., Walczak, H., & Kulms, D. (2013). Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. Cell Death and Disease, 4, Article 7. https://doi.org/10.1038/cddis.2013.249
    12. Strotbek, M., Florin, L., Koenitzer, J., Tolstrup, A., Kaufmann, H., Hausser, A., & Olayioye, M. A. (2013). Stable microRNA expression enhances therapeutic antibody productivity of Chinese hamster ovary cells. Metabolic Engineering, 20, 157–166. https://doi.org/10.1016/j.ymben.2013.10.005

  15. 2012

    1. Winkel, C., Neumann, S., Surulescu, C., & Scheurich, P. (2012). A minimal mathematical model for the initial molecular interactions of death receptor signalling. Mathematical Biosciences and Engineering, 9, Article 3. https://doi.org/10.3934/mbe.2012.9.663
    2. Hutt, M., Färber-Schwarz, A., Unverdorben, F., Richter, F., & Kontermann, R. E. (2012). Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains. Journal of Biological Chemistry, 287, Article 7. https://doi.org/10.1074/jbc.M111.311522
    3. Eisler, S. A., Fuchs, Y. F., Pfizenmaier, K., & Hausser, A. (2012). G-PKDrep-live, a genetically encoded FRET reporter to measure PKD activity at the trans-Golgi-network. Biotechnology Journal, 7, Article 1. https://doi.org/10.1002/biot.201100273
    4. Kontermann, R. E. (2012). Dual targeting strategies with bispecific antibodies. mAbs, 4, Article 2. https://doi.org/10.4161/mabs.4.2.19000
    5. Seifert, O., Plappert, A., Heidel, N., Fellermeier, S., Messerschmidt, S. K. E., Richter, F., & Kontermann, R. E. (2012). The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity. Protein Engineering, Design and Selection, 25, Article 10. https://doi.org/10.1093/protein/gzs059
    6. Hornig, N., Kermer, V., Frey, K., Diebolder, P., Kontermann, R. E., & Müller, D. (2012). Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. Journal of Immunotherapy, 35, Article 5. https://doi.org/10.1097/CJI.0b013e3182594387
    7. Kontermann, R. E. (2012). Antibody-cytokine fusion proteins. Archives of Biochemistry and Biophysics, 526, Article 2. https://doi.org/10.1016/j.abb.2012.03.001
    8. Unverdorben, F., Färber-Schwarz, A., Richter, F., Hutt, M., & Kontermann, R. E. (2012). Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A. Protein Engineering, Design and Selection, 25, Article 2. https://doi.org/10.1093/protein/gzr061
    9. Moosmann, A., Gerlach, E., Lindner, R., & Böttinger, H. (2012). Purification of a PEGylated single chain Fv. Journal of Chromatography A, 1236, 90–96. https://doi.org/10.1016/j.chroma.2012.03.004
    10. Kermer, V., Baum, V., Hornig, N., Kontermann, R. E., & Müller, D. (2012). An Antibody Fusion Protein for Cancer Immunotherapy Mimicking IL-15 \textlessi\textgreatertrans\textless/i\textgreater -Presentation at the Tumor Site. Molecular Cancer Therapeutics, 11, Article 6. https://doi.org/10.1158/1535-7163.MCT-12-0019
    11. Siegemund, M., Pollak, N., Seifert, O., Wahl, K., Hanak, K., Vogel, A., Nussler, A. K., Göttsch, D., Münkel, S., Bantel, H., Kontermann, R. E., & Pfizenmaier, K. (2012). Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. Cell Death and Disease, 3, Article 4. https://doi.org/10.1038/cddis.2012.29
    12. Witt, J., Konrath, F., Sawodny, O., Ederer, M., Kulms, D., & Sauter, T. (2012). Analysing the role of UVB-induced translational inhibition and PP2Ac deactivation in NF-κB signalling using a minimal mathematical model. PLoS ONE, 7, Article 7. https://doi.org/10.1371/journal.pone.0040274
    13. Schildknecht, S., Kirner, S., Henn, A., Gasparic, K., Pape, R., Efremova, L., Maier, O., Fischer, R., & Leist, M. (2012). Characterization of mouse cell line IMA 2.1 as a potential model system to study astrocyte functions. Altex, 29, Article 3. https://doi.org/10.14573/altex.2012.3.261
    14. Müller, D. (2012). Targeted cancer immunotherapy: Mimicking physiological trans-presentation of IL-15. OncoImmunology, 1, Article 7. https://doi.org/10.4161/onci.20824
    15. Heering, J., Weis, N., Holeiter, M., Neugart, F., Staebler, A., Fehm, T. N., Bischoff, A., Schiller, J., Duss, S., Schmid, S., Korte, T., Herrmann, A., & Olayioye, M. A. (2012). Loss of the ceramide transfer protein augments EGF receptor signaling in breast cancer. Cancer Research, 72, Article 11. https://doi.org/10.1158/0008-5472.CAN-11-3069
    16. Hasenauer, J., Heinrich, J., Doszczak, M., Scheurich, P., Weiskopf, D., & Allgöwer, F. (2012). A visual analytics approach for models of heterogeneous cell populations. Eurasip Journal on Bioinformatics and Systems Biology, 2012, Article 1. https://doi.org/10.1186/1687-4153-2012-4
    17. Olayioye, M. A., & Hausser, A. (2012). Integration of non-vesicular and vesicular transport processes at the Golgi complex by the PKD-CERT network. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1821, Article 8. https://doi.org/10.1016/j.bbalip.2011.12.005
    18. Huck, B., Kemkemer, R., Franz-Wachtel, M., Macek, B., Hausser, A., & Olayioye, M. A. (2012). GIT1 Phosphorylation on Serine 46 by PKD3 regulates paxillin trafficking and cellular protrusive activity. Journal of Biological Chemistry, 287, Article 41. https://doi.org/10.1074/jbc.M112.374652
    19. Franz-Wachtel, M., Eisler, S. A., Krug, K., Wahl, S., Carpy, A., Nordheim, A., Pfizenmaier, K., Hausser, A., & Macek, B. (2012). Global Detection of Protein Kinase D-dependent Phosphorylation Events in Nocodazole-treated Human Cells. Molecular & Cellular Proteomics, 11, Article 5. https://doi.org/10.1074/mcp.M111.016014
    20. Holeiter, G., Bischoff, A., Braun, A. C., Huck, B., Erlmann, P., Schmid, S., Herr, R., Brummer, T., & Olayioye, M. A. (2012). The RhoGAP protein deleted in liver cancer 3 (DLC3) is essential for adherens junctions integrity. Oncogenesis, 1, Article 6. https://doi.org/10.1038/oncsis.2012.13
    21. Richter, C., Messerschmidt, S., Holeiter, G., Tepperink, J., Osswald, S., Zappe, A., Branschadel, M., Boschert, V., Mann, D. A., Scheurich, P., & Krippner-Heidenreich, A. (2012). The Tumor Necrosis Factor Receptor Stalk Regions Define Responsiveness to Soluble versus Membrane-Bound Ligand. Molecular and Cellular Biology, 32, Article 13. https://doi.org/10.1128/MCB.06458-11
    22. Mack, K., Rüger, R., Fellermeier, S., Seifert, O., & Kontermann, R. E. (2012). Dual Targeting of Tumor Cells with Bispecific Single-Chain Fv-Immunoliposomes. Antibodies, 1, Article 3. https://doi.org/10.3390/antib1020199
    23. Lopez-Ramirez, M. A., Fischer, R., Torres-Badillo, C. C., Davies, H. A., Logan, K., Pfizenmaier, K., Male, D. K., Sharrack, B., & Romero, I. A. (2012). Role of Caspases in Cytokine-Induced Barrier Breakdown in Human Brain Endothelial Cells. The Journal of Immunology, 189, Article 6. https://doi.org/10.4049/jimmunol.1103460
    24. Kempkes, C., Rattenholl, A., Buddenkotte, J., Strozyk, E., Eberle, J., Hausser, A., Cevikbas, F., Schneider, S. W., & Steinhoff, M. (2012). Proteinase-activated receptors 1 and 2 regulate invasive behavior of human melanoma cells via activation of protein kinase D1. Journal of Investigative Dermatology, 132, Article 2. https://doi.org/10.1038/jid.2011.314
    25. Neumann, S., Bidon, T., Branschädel, M., Krippner-Heidenreich, A., Scheurich, P., & Doszczak, M. (2012). The transmembrane domains of TNF-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2 co-regulate apoptotic signaling capacity. PLoS ONE, 7, Article 8. https://doi.org/10.1371/journal.pone.0042526
    26. Daub, M., Waldherr, S., Allgöwer, F., Scheurich, P., & Schneider, G. (2012). Death wins against life in a spatially extended model of the caspase-3/8 feedback loop. BioSystems, 108, Article 1–3. https://doi.org/10.1016/j.biosystems.2012.01.006

  16. 2011

    1. Fischer, R., Maier, O., Naumer, M., Krippner-Heidenreich, A., Scheurich, P., & Pfizenmaier, K. (2011). Ligand-induced internalization of TNF receptor 2 mediated by a di-leucin motif is dispensable for activation of the NFκB pathway. Cellular Signalling, 23, Article 1. https://doi.org/10.1016/j.cellsig.2010.08.016
    2. Kontermann, R. E. (2011). Strategies for extended serum half-life of protein therapeutics. Current Opinion in Biotechnology, 22, Article 6. https://doi.org/10.1016/j.copbio.2011.06.012
    3. Barisić, S., Nagel, A. C., Franz-Wachtel, M., MacEk, B., Preiss, A., Link, G., Maier, D., & Hausser, A. (2011). Phosphorylation of ser 402 impedes phosphatase activity of slingshot 1. EMBO Reports, 12, Article 6. https://doi.org/10.1038/embor.2011.53
    4. Ziegler, S., Eiseler, T., Scholz, R.-P., Beck, A., Link, G., & Hausser, A. (2011). A novel protein kinase D phosphorylation site in the tumor suppressor Rab interactor 1 is critical for coordination of cell migration. Molecular Biology of the Cell, 22, Article 5. https://doi.org/10.1091/mbc.E10-05-0427
    5. Moosmann, A., Blath, J., Lindner, R., Müller, E., & Böttinger, H. (2011). Aldehyde PEGylation kinetics: A standard protein versus a pharmaceutically relevant single chain variable fragment. Bioconjugate Chemistry, 22, Article 8. https://doi.org/10.1021/bc200090x
    6. Schliemann, M., Bullinger, E., Borchers, S., Allgöwer, F., Findeisen, R., & Scheurich, P. (2011). Heterogeneity reduces sensitivity of cell death for TNF-Stimuli. BMC Systems Biology, 5, 204. https://doi.org/10.1186/1752-0509-5-204
    7. Wajant, H., & Scheurich, P. (2011). TNFR1-induced activation of the classical NF-κB pathway. FEBS Journal, 278, Article 6. https://doi.org/10.1111/j.1742-4658.2011.08015.x
    8. Pfizenmaier, K., & Szymkowski, D. E. (2011). Workshop Summary: Introduction to Rational Design of New Means for Therapeutic Modulation of Function of the TNF Family. Adv Exp Med Biol, 691, 487–491. https://doi.org/10.1007/978-1-4419-6612-4_50
    9. Hörnle, M., Peters, N., Thayaparasingham, B., Vörsmann, H., Kashkar, H., & Kulms, D. (2011). Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis. Oncogene, 30, Article 5. https://doi.org/10.1038/onc.2010.434
    10. Witt, J., Barisic, S., Sawodny, O., Ederer, M., Kulms, D., & Sauter, T. (2011). Modeling time delay in the NFκB signaling pathway following low dose IL-1 stimulation. EURASIP Journal on Bioinformatics & Systems Biology, 2011, Article 1. https://doi.org/10.1186/1687-4153-2011-3
    11. Hasenauer, J., Waldherr, S., Doszczak, M., Radde, N., Scheurich, P., & Allgöwer, F. (2011). Identification of models of heterogeneous cell populations from population snapshot data. BMC Bioinformatics, 12, 125. https://doi.org/10.1186/1471-2105-12-125
    12. Gerspach, J., Pfizenmaier, K., & Wajant, H. (2011). Therapeutic Targeting of CD95 and the TRAIL Death Receptors. Recent Patents on Anti-Cancer Drug Discovery, 6, Article 3. https://doi.org/10.2174/157489211796957739
    13. Gerspach, J., Schneider, B., Müller, N., Otz, T., Wajant, H., & Pfizenmaier, K. (2011). Genetic engineering of death ligands for improvement of therapeutic activity. Advances in Experimental Medicine and Biology, 691, 507–519. https://doi.org/10.1007/978-1-4419-6612-4_53
    14. Scholz, R. P., Gustafsson, J. O. R., Hoffmann, P., Jaiswal, M., Ahmadian, M. R., Eisler, S. A., Erlmann, P., Schmid, S., Hausser, A., & Olayioye, M. A. (2011). The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation. Experimental Cell Research, 317, Article 4. https://doi.org/10.1016/j.yexcr.2010.11.003
    15. Chertoff, M., Paolo, N. D., Schoeneberg, A., Depino, A., Ferrari, C., Wurst, W., Pfizenmaier, K., Eisel, U., & Pitossi, F. (2011). Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor α in the nigrostriatal dopaminergic circuit of adult mice. Experimental Neurology, 227, Article 2. https://doi.org/10.1016/j.expneurol.2010.11.010
    16. Niessner, H., Beck, D., Sinnberg, T., Lasithiotakis, K., MacZey, E., Gogel, J., Venturelli, S., Berger, A., Mauthe, M., Toulany, M., Flaherty, K., Schaller, M., Schadendorf, D., Proikas-Cezanne, T., Schittek, B., Garbe, C., Kulms, D., & Meier, F. (2011). The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. Journal of Investigative Dermatology, 131, Article 2. https://doi.org/10.1038/jid.2010.297
    17. Fischer, R., Maier, O., Siegemund, M., Wajant, H., Scheurich, P., & Pfizenmaier, K. (2011). A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death. PLoS ONE, 6, Article 11. https://doi.org/10.1371/journal.pone.0027621
    18. Ranzinger, J., Rustom, A., Abel, M., Leyh, J., Kihm, L., Witkowski, M., Scheurich, P., Zeier, M., & Schwenger, V. (2011). Nanotube action between human mesothelial cells reveals novel aspects of inflammatory responses. PLoS ONE, 6, Article 12. https://doi.org/10.1371/journal.pone.0029537
    19. Krenz, B., Neugart, F., Kleinow, T., & Jeske, H. (2011). Self-interaction of Abutilon mosaic virus replication initiator protein (Rep) in plant cell nuclei. Virus Research, 161, Article 2. https://doi.org/10.1016/j.virusres.2011.07.020
    20. Ellwanger, K., Kienzle, C., Lutz, S., Jin, Z.-G., Wiekowski, M. T., Pfizenmaier, K., & Hausser, A. (2011). Protein kinase D controls voluntary-running-induced skeletal muscle remodelling. Biochemical Journal, 440, Article 3. https://doi.org/10.1042/BJ20101980
    21. Gehrmann, M., Doß, B. T., Wagner, M., Zettlitz, K. A., Kontermann, R. E., Foulds, G., Pockley, A. G., & Multhoff, G. (2011). A novel expression and purification system for the production of enzymatic and biologically active human granzyme B. Journal of Immunological Methods, 371, Article 1–2. https://doi.org/10.1016/j.jim.2011.06.007
    22. Dengler, M. A., Staiger, A. M., Gutekunst, M., Hofmann, U., Doszczak, M., Scheurich, P., Schwab, M., Aulitzky, W. E., & van der Kuip, H. (2011). Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis. PLoS ONE, 6, Article 9. https://doi.org/10.1371/journal.pone.0025139
    23. Krone, M., Falk, M., Rehm, S., Pleiss, J., & Ertl, T. (2011). Interactive Exploration of Protein Cavities. Computer Graphics Forum, 30, Article 3. https://doi.org/10.1111/j.1467-8659.2011.01916.x

  17. 2010

    1. Kontermann, R. E. (2010). Alternative antibody formats. Current Opinion in Molecular Therapeutics, 12, Article 2. https://www.ncbi.nlm.nih.gov/pubmed/20373261
    2. Becker, E., Florin, L., Pfizenmaier, K., & Kaufmann, H. (2010). Evaluation of a combinatorial cell engineering approach to overcome apoptotic effects in XBP-1(s) expressing cells. Journal of Biotechnology, 146, Article 4. https://doi.org/10.1016/j.jbiotec.2009.11.018
    3. Murphy, N. C., Biankin, A. V., Millar, E. K. A., McNeil, C. M., O’Toole, S. A., Segara, D., Crea, P., Olayioye, M. A., Lee, C. S., Fox, S. B., Morey, A. L., Christie, M., Musgrove, E. A., Daly, R. J., Lindeman, G. J., Henshall, S. M., Visvader, J. E., & Sutherland, R. L. (2010). Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. International Journal of Cancer, 126, Article 6. https://doi.org/10.1002/ijc.24826
    4. Zettlitz, K. A., Lorenz, V., Landauer, K., Münkel, S., Herrmann, A., Scheurich, P., Pfizenmaier, K., & Kontermann, R. E. (2010). ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. mAbs, 2, Article 6. https://doi.org/10.4161/mabs.2.6.13583
    5. Boschert, V., Krippner-Heidenreich, A., Branschädel, M., Tepperink, J., Aird, A., & Scheurich, P. (2010). Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNFR2. Cellular Signalling, 22, Article 7. https://doi.org/10.1016/j.cellsig.2010.02.011
    6. Anliker, B., Abel, T., Kneissl, S., Hlavaty, J., Caputi, A., Brynza, J., Schneider, I. C., Münch, R. C., Petznek, H., Kontermann, R. E., Koehl, U., Johnston, I. C. D., Keinänen, K., Müller, U. C., Hohenadl, C., Monyer, H., Cichutek, K., & Buchholz, C. J. (2010). Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nature Methods, 7, 929––. http://dx.doi.org/10.1038/nmeth.1514
    7. Eiseler, T., Hausser, A., De Kimpe, L., Van Lint, J., & Pfizenmaier, K. (2010). Protein kinase D controls actin polymerization and cell motility through phosphorylation of cortactin. Journal of Biological Chemistry, 285, Article 24. https://doi.org/10.1074/jbc.M109.093880
    8. Hasenauer, J., Waldherr, S., Doszczak, M., Scheurich, P., & Allgöwer, F. (2010). Density-based modeling and identification of biochemical networks in cell populations. IFAC Proceedings Volumes (IFAC-PapersOnline), 9, Article PART 1. https://doi.org/10.3182/20100705-3-BE-2011.0038
    9. Smolders, I., Smets, I., Maier, O., VandeVen, M., Steels, P., & Ameloot, M. (2010). Simvastatin interferes with process outgrowth and branching of oligodendrocytes. Journal of Neuroscience Research, 88, Article 15. https://doi.org/10.1002/jnr.22490
    10. Baum, P., Fundel-Clemens, K., Kreuz, S., Kontermann, R. E., Weith, A., Mennerich, D., & Rippmann, J. F. (2010). Off-target analysis of control siRNA molecules reveals important differences in the cytokine profile and inflammation response of human fibroblasts. Oligonucleotides, 20, Article 1. https://doi.org/10.1089/oli.2009.0213
    11. Rothdiener, M., Müller, D., Castro, P. G., Scholz, A., Schwemmlein, M., Fey, G., Heidenreich, O., & Kontermann, R. E. (2010). Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems. Journal of Controlled Release, 144, Article 2. https://doi.org/10.1016/j.jconrel.2010.02.020
    12. Joffroy, C. M., Buck, M. B., Stope, M. B., Popp, S. L., Pfizenmaier, K., & Knabbe, C. (2010). Antiestrogens induce transforming growth factor $\beta$-mediated immunosuppression in breast cancer. Cancer Research, 70, Article 4. https://doi.org/10.1158/0008-5472.CAN-09-3292
    13. Gerken, M., Krippner-Heidenreich, A., Steinert, S., Willi, S., Neugart, F., Zappe, A., Wrachtrup, J., Tietz, C., & Scheurich, P. (2010). Fluorescence correlation spectroscopy reveals topological segregation of the two tumor necrosis factor membrane receptors. Biochimica et Biophysica Acta - Biomembranes, 1798, Article 6. https://doi.org/10.1016/j.bbamem.2010.02.021
    14. Moosmann, A., Christel, J., Boettinger, H., & Mueller, E. (2010). Analytical and preparative separation of PEGylated lysozyme for the characterization of chromatography media. Journal of Chromatography A, 1217, Article 2. https://doi.org/10.1016/j.chroma.2009.11.031
    15. Rothdiener, M., Beuttler, J., Messerschmidt, S. K., & Kontermann, R. E. (2010). Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes. Methods in Molecular Biology (Clifton, N.J.), 624, 295–308. https://doi.org/10.1007/978-1-60761-609-2_20
    16. Schneider, B., Münkel, S., Krippner-Heidenreich, A., Grunwald, I., Wels, W. S., Wajant, H., Pfizenmaier, K., & Gerspach, J. (2010). Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. Cell Death and Disease, 1, Article 8. https://doi.org/10.1038/cddis.2010.45
    17. Branschädel, M., Aird, A., Zappe, A., Tietz, C., Krippner-Heidenreich, A., & Scheurich, P. (2010). Dual function of cysteine rich domain (CRD) 1 of TNF receptor type 1: Conformational stabilization of CRD2 and control of receptor responsiveness. Cellular Signalling, 22, Article 3. https://doi.org/10.1016/j.cellsig.2009.10.011
    18. Waldherr, S., Hasenauer, J., Doszczak, M., Scheurich, P., & Allgöwer, F. (2010). Global uncertainty analysis for a model of TNF-induced NF-κB signalling. In Lecture Notes in Control and Information Sciences (Vol. 407, pp. 365–377). Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-16135-3-29
    19. Hasenauer, J., Waldherr, S., Radde, N., Doszczak, M., Scheurich, P., & Allgöwer, F. (2010). A maximum likelihood estimator for parameter distributions in heterogeneous cell populations. Procedia Computer Science, 1, Article 1. https://doi.org/10.1016/j.procs.2010.04.185
    20. Brandt, S., Ellwanger, K., Beuter-Gunia, C., Schuster, M., Hausser, A., Schmitz, I., & Beer-Hammer, S. (2010). SLy2 targets the nuclear SAP30/HDAC1 complex. International Journal of Biochemistry and Cell Biology, 42, Article 9. https://doi.org/10.1016/j.biocel.2010.05.004
    21. Barisic, S., Schmidt, C., Walczak, H., & Kulms, D. (2010). Tyrosine phosphatase inhibition triggers sustained canonical serine-dependent NFκB activation via Src-dependent blockade of PP2A. Biochemical Pharmacology, 80, Article 4. https://doi.org/10.1016/j.bcp.2010.04.028
    22. Müller, E., Josic, D., Schröder, T., & Moosmann, A. (2010). Solubility and binding properties of PEGylated lysozyme derivatives with increasing molecular weight on hydrophobic-interaction chromatographic resins. Journal of Chromatography A, 1217, Article 28. https://doi.org/10.1016/j.chroma.2010.05.016
    23. Baum, P., Schmid, R., Ittrich, C., Rust, W., Fundel-Clemens, K., Siewert, S., Baur, M., Mara, L., Gruenbaum, L., Heckel, A., Eils, R., Kontermann, R. E., Roth, G. J., Gantner, F., Schnapp, A., Park, J. E., Weith, A., Quast, K., & Mennerich, D. (2010). Phenocopy - a strategy to qualify chemical compounds during hit-to-lead and/or lead optimization. PLoS ONE, 5, Article 12. https://doi.org/10.1371/journal.pone.0014272
    24. Müller, D., & Kontermann, R. E. (2010). Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs, 24, Article 2. https://doi.org/10.2165/11530960-000000000-00000
    25. Hopp, J., Hornig, N., Zettlitz, K. A., Schwarz, A., Fuß, N., Müller, D., & Kontermann, R. E. (2010). The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Engineering, Design and Selection, 23, Article 11. https://doi.org/10.1093/protein/gzq058
    26. Zettlitz, K. A., Seitter, J., Müller, D., & Kontermann, R. E. (2010). Humanization of a mouse monoclonal antibody directed against a cell surface-exposed epitope of membrane-associated heat shock protein 70 (Hsp70). Molecular Biotechnology, 46, Article 3. https://doi.org/10.1007/s12033-010-9298-x

  18. 2009

    1. Florin, L., Pegel, A., Becker, E., Hausser, A., Olayioye, M. A., & Kaufmann, H. (2009). Heterologous expression of the lipid transfer protein CERT increases therapeutic protein productivity of mammalian cells. Journal of Biotechnology, 141, Article 1–2. https://doi.org/10.1016/j.jbiotec.2009.02.014
    2. Thayaparasingham, B., Kunz, A., & Kulms, D. (2009). Sensitization of melanoma cells to TRAIL by UVB-induced and NF-κB-mediated downregulation of xIAP. Oncogene, 28, Article 3. https://doi.org/10.1038/onc.2008.397
    3. Kontermann, R. E. (2009). Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs, 23, Article 2. https://doi.org/10.2165/00063030-200923020-00003
    4. Breindl, C., Waldherr, S., Hausser, A., & Allgöwer, F. (2009). MODELING COFILIN MEDIATED REGULATION OF CELL MIGRATION AS A BIOCHEMICAL TWO-INPUT SWITCH. Proc.Of the 3rd Foundations of Systems Biology in Engineering (FOSBE), 60–63. https://lirias.kuleuven.be/bitstream/123456789/568203/1/BreindlWal2009.pdf
    5. Erlmann, P., Schmid, S., Horenkamp, F. A., Geyer, M., Pomorski, T. G., & Olayioye, M. A. (2009). DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain. Molecular Biology of the Cell, 20, Article 20. https://doi.org/10.1091/mbc.E09-03-0247
    6. Peterburs, P., Heering, J., Link, G., Pfizenmaier, K., Olayioye, M. A., & Hausser, A. (2009). Protein kinase D regulates cell migration by direct phosphorylation of the cofilin phosphatase slingshot 1 like. Cancer Research, 69, Article 14. https://doi.org/10.1158/0008-5472.CAN-09-0718
    7. Scholz, R.-P., Regner, J., Theil, A., Erlmann, P., Holeiter, G., Jähne, R., Schmid, S., Hausser, A., & Olayioye, M. a. (2009). DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling. Journal of Cell Science, 122, Article Pt 1. https://doi.org/10.1242/jcs.036251
    8. Witt, J., Barisic, S., Schumann, E., Allgöwer, F., Sawodny, O., Sauter, T., & Kulms, D. (2009). Mechanism of PP2A-mediated IKKβ dephosphorylation: A systems biological approach. BMC Systems Biology, 3, 71. https://doi.org/10.1186/1752-0509-3-71
    9. Messerschmidt, S. K. E., Musyanovych, A., Altvater, M., Scheurich, P., Pfizenmaier, K., Landfester, K., & Kontermann, R. E. (2009). Targeted lipid-coated nanoparticles: Delivery of tumor necrosis factor-functionalized particles to tumor cells. Journal of Controlled Release, 137, Article 1. https://doi.org/10.1016/j.jconrel.2009.03.010
    10. Cowell, C. F., Doppler, H., Yan, I. K., Hausser, A., Umezawa, Y., & Storz, P. (2009). Mitochondrial diacylglycerol initiates protein-kinase-D1-mediated ROS signaling. Journal of Cell Science, 122, Article 7. https://doi.org/10.1242/jcs.041061
    11. Fuchs, Y. F., Eisler, S. A., Link, G., Schlicker, O., Bunt, G., Pfizenmaier, K., & Hausser, A. (2009). A Golgi PKD activity reporter reveals a crucial role of PKD in nocodazole-induced Golgi dispersal. Traffic, 10, Article 7. https://doi.org/10.1111/j.1600-0854.2009.00918.x
    12. Gerspach, J., Pfizenmaier, K., & Wajant, H. (2009). Improving TNF as a cancer therapeutic: Tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects. BioFactors, 35, Article 4. https://doi.org/10.1002/biof.50
    13. Kontermann, R. E., Scheurich, P., & Pfizenmaier, K. (2009). Antagonists of TNF action: clinical experience and new developments. Expert Opinion on Drug Discovery, 4, Article 3. https://doi.org/10.1517/17460440902785167
    14. Wyzgol, A., Muller, N., Fick, A., Munkel, S., Grigoleit, G. U., Pfizenmaier, K., & Wajant, H. (2009). Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand. The Journal of Immunology, 183, Article 3. https://doi.org/10.4049/jimmunol.0802597
    15. Schlatter, R., Schmich, K., Vizcarra, I. A., Scheurich, P., Sauter, T., Borner, C., Ederer, M., Merfort, I., & Sawodny, O. (2009). ON/OFF and beyond - A Boolean model of apoptosis. PLoS Computational Biology, 5, Article 12. https://doi.org/10.1371/journal.pcbi.1000595
    16. Stork, R., Campigna, E., Robert, B., Müller, D., & Kontermann, R. E. (2009). Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. Journal of Biological Chemistry, 284, Article 38. https://doi.org/10.1074/jbc.M109.027078
    17. Ranzinger, J., Krippner-Heidenreich, A., Haraszti, T., Bock, E., Tepperink, J., Spatz, J. P., & Scheurich, P. (2009). Nanoscale arrangement of apoptotic ligands reveals a demand for a minimal lateral distance for efficient death receptor activation. Nano Letters, 9, Article 12. https://doi.org/10.1021/nl902429b
    18. Huber, H., Bullinger, E., & Rehm, M. (2009). Systems Biology Approaches to the Study of Apoptosis. In Z. Dong & X.-M. Yin (Eds.), Essentials of Apoptosis: A Guide for Basic and Clinical Research (pp. 283–297). Humana Press. https://doi.org/10.1007/978-1-60327-381-7_12
    19. Heering, J., Erlmann, P., & Olayioye, M. A. (2009). Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration. Experimental Cell Research, 315, Article 15. https://doi.org/10.1016/j.yexcr.2009.05.022
    20. Gerspach, J., Wajant, H., & Pfizenmaier, K. (2009). Death ligands designed to kill: Development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands. Results and Problems in Cell Differentiation, 49, 241–273. https://doi.org/10.1007/400_2008_22
    21. Beuttler, J., Rothdiener, M., Müller, D., Frejd, F. Y., & Kontermann, R. E. (2009). Targeting of Epidermal Growth Factor Receptor (EGFR)-Expressing Tumor Cells with Sterically Stabilized Affibody Liposomes (SAL). Bioconjugate Chemistry, 20, Article 6. https://doi.org/10.1021/bc900061v
    22. Wicovsky, A., Henkler, F., Salzmann, S., Scheurich, P., Kneitz, C., & Wajant, H. (2009). Tumor necrosis factor receptor-associated factor-1 enhances proinflammatory TNF receptor-2 signaling and modifies TNFR1-TNFR2 cooperation. Oncogene, 28, Article 15. https://doi.org/10.1038/onc.2009.29
    23. Czöndör, K., Ellwanger, K., Fuchs, Y. F., Lutz, S., Gulyás, M., Mansuy, I. M., Hausser, A., Pfizenmaier, K., & Schlett, K. (2009). Protein kinase D controls the integrity of Golgi apparatus and the maintenance of dendritic arborization in hippocampal neurons. Molecular Biology of the Cell, 20, Article 7. https://doi.org/10.1091/mbc.E08-09-0957
    24. Sinnberg, T., Lasithiotakis, K., Niessner, H., Schittek, B., Flaherty, K. T., Kulms, D., Maczey, E., Campos, M., Gogel, J., Garbe, C., & Meier, F. (2009). Inhibition of PI3K-AKT-mTOR Signaling Sensitizes Melanoma Cells to Cisplatin and Temozolomide. Journal of Investigative Dermatology, 129, Article 6. https://doi.org/10.1038/jid.2008.379
    25. Ahmadvand, D., Rasaee, M. J., Rahbarizadeh, F., Kontermann, R. E., & Sheikholislami, F. (2009). Cell selection and characterization of a novel human endothelial cell specific nanobody. Molecular Immunology, 46, Article 8–9. https://doi.org/10.1016/j.molimm.2009.01.021

  19. 2008

    1. Singer-Krüger, B., Lasić, M., Bürger, A. M., Haußer, A., Pipkorn, R., & Wang, Y. (2008). Yeast and human Ysl2p/hMon2 interact with Gga adaptors and mediate their subcellular distribution. EMBO Journal, 27, Article 10. https://doi.org/10.1038/emboj.2008.75
    2. Ellwanger, K., Pfizenmaier, K., Lutz, S., & Hausser, A. (2008). Expression patterns of protein kinase D 3 during mouse development. BMC Developmental Biology, 8, 47. https://doi.org/10.1186/1471-213X-8-47
    3. Müller, D., Frey, K., & Kontermann, R. E. (2008). A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy. Journal of Immunotherapy, 31, Article 8. https://doi.org/10.1097/CJI.0b013e31818353e9
    4. Messerschmidt, S. K. E., Kolbe, A., Müller, D., Knoll, M., Pleiss, J., & Kontermann, R. E. (2008). Novel single-chain Fv′ formats for the generation of immunoliposomes by site-directed coupling. Bioconjugate Chemistry, 19, Article 1. https://doi.org/10.1021/bc700349k
    5. Lasithiotakis, K. G., Sinnberg, T. W., Schittek, B., Flaherty, K. T., Kulms, D., Maczey, E., Garbe, C., & Meier, F. E. (2008). Combined Inhibition of MAPK and mTOR Signaling Inhibits Growth, Induces Cell Death, and Abrogates Invasive Growth of Melanoma Cells. Journal of Investigative Dermatology, 128, Article 8. https://doi.org/10.1038/jid.2008.44
    6. Stork, R., Zettlitz, K. A., Müller, D., Rether, M., Hanisch, F. G., & Kontermann, R. E. (2008). N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. Journal of Biological Chemistry, 283, Article 12. https://doi.org/10.1074/jbc.M709179200
    7. Müller, D., Trunk, G., Sichelstiel, A., Zettlitz, K. A., Quintanilla, M., & Kontermann, R. E. (2008). Murine endoglin-specific single-chain Fv fragments for the analysis of vascular targeting strategies in mice. Journal of Immunological Methods, 339, Article 1. https://doi.org/10.1016/j.jim.2008.08.008
    8. Müller, N., Wyzgol, A., Münkel, S., Pfizenmaier, K., & Wajant, H. (2008). Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization. FEBS Journal, 275, Article 9. https://doi.org/10.1111/j.1742-4658.2008.06382.x
    9. Chang, H. H., Wang, W., Bong, S. J., Wong, C., Hausser, A., Pfizenmaier, K., McKinsey, T. A., Olson, E. N., & Jin, Z. G. (2008). Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis. Journal of Biological Chemistry, 283, Article 21. https://doi.org/10.1074/jbc.M800264200
    10. Holeiter, G., Heering, J., Erlmann, P., Schmid, S., Jähne, R., & Olayioye, M. A. (2008). Deleted in liver cancer 1 controls cell migration through a dia1-dependent signaling pathway. Cancer Research, 68, Article 21. https://doi.org/10.1158/0008-5472.CAN-08-0984
    11. Johnson, T. S., Mahnke, K., Storn, V., Schönfeld, K., Ring, S., Nettelbeck, D. M., Haisma, H. J., Le Gall, F., Kontermann, R. E., & Enk, A. H. (2008). Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule. Clinical Cancer Research, 14, Article 24. https://doi.org/10.1158/1078-0432.CCR-08-1474
    12. Krippner-Heidenreich, A., Grunwald, I., Zimmermann, G., Kuhnle, M., Gerspach, J., Sterns, T., Shnyder, S. D., Gill, J. H., Mannel, D. N., Pfizenmaier, K., & Scheurich, P. (2008). Single-Chain TNF, a TNF Derivative with Enhanced Stability and Antitumoral Activity. The Journal of Immunology, 180, Article 12. https://doi.org/10.4049/jimmunol.180.12.8176
    13. Kontermann, R. E., Münkel, S., Neumeyer, J., Müller, D., Branschädel, M., Scheurich, P., & Pfizenmaier, K. (2008). A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action. Journal of Immunotherapy, 31, Article 3. https://doi.org/10.1097/CJI.0b013e31816a88f9
    14. Müller, E., & Faude, A. (2008). Investigation of salt properties with electro-acoustic measurements and their effect on dynamic binding capacity in hydrophobic interaction chromatography. Journal of Chromatography A, 1177, Article 2. https://doi.org/10.1016/j.chroma.2007.11.008
    15. BECKER, E., FLORIN, L., PFIZENMAIER, K., & KAUFMANN, H. (2008). An XBP-1 dependent bottle-neck in production of IgG subtype antibodies in chemically defined serum-free Chinese hamster ovary (CHO) fed-batch processes. Journal of Biotechnology, 135, Article 2. https://doi.org/10.1016/j.jbiotec.2008.03.008
    16. Barisic, S., Strozyk, E., Peters, N., Walczak, H., & Kulms, D. (2008). Identification of PP2A as a crucial regulator of the NF-$\kappa$B feedback loop: Its inhibition by UVB turns NF-κB into a pro-apoptotic factor. Cell Death and Differentiation, 15, Article 11. https://doi.org/10.1038/cdd.2008.98

  20. 2007

    1. Maier, D., Nagel, A. C., Gloc, H., Hausser, A., Kugler, S. J., Wech, I., & Preiss, A. (2007). Protein Kinase D regulates several aspects of development in Drosophila melanogaster. BMC Developmental Biology, 7, 74. https://doi.org/10.1186/1471-213X-7-74
    2. Stork, R., Müller, D., & Kontermann, R. E. (2007). A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Engineering, Design and Selection, 20, Article 11. https://doi.org/10.1093/protein/gzm061
    3. Meier, F., Busch, S., Lasithiotakis, K., Kulms, D., Garbe, C., Maczey, E., Herlyn, M., & Schittek, B. (2007). Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. British Journal of Dermatology, 156, Article 6. https://doi.org/10.1111/j.1365-2133.2007.07821.x
    4. Faude, A., Zacher, D., Müller, E., & Böttinger, H. (2007). Fast determination of conditions for maximum dynamic capacity in cation-exchange chromatography of human monoclonal antibodies. Journal of Chromatography A, 1161, Article 1–2. https://doi.org/10.1016/j.chroma.2007.03.114
    5. Olayioye, M. A., Buchholz, M., Schmid, S., Schöffler, P., Hoffmann, P., & Pomorski, T. (2007). Phosphorylation of StarD10 on serine 284 by casein kinase II modulates its lipid transfer activity. Journal of Biological Chemistry, 282, Article 31. https://doi.org/10.1074/jbc.M701990200
    6. Xu, X., Ha, C. H., Wong, C., Wang, W., Hausser, A., Pfizenmaier, K., Olson, E. N., McKinsey, T. A., & Jin, Z. G. (2007). Angiotensin II stimulates protein kinase D-dependent histone deacetylase 5 phosphorylation and nuclear export leading to vascular smooth muscle cell hypertrophy. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, Article 11. https://doi.org/10.1161/ATVBAHA.107.151704
    7. Baum, P., Müller, D., Rüger, R., & Kontermann, R. E. (2007). Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells. Journal of Drug Targeting, 15, Article 6. https://doi.org/10.1080/10611860701453034
    8. Witt, J., Husser, S., Kulms, D., Barisic, S., Sawodny, O., & Sauter, T. (2007). Modeling of IL-1 induced NF-κB signaling and analysis of additional UVB influence. Proceedings of the SICE Annual Conference, 1353–1358. https://doi.org/10.1109/SICE.2007.4421193
    9. Hesse, A., Kosmides, D., Kontermann, R. E., & Nettelbeck, D. M. (2007). Tropism Modification of Adenovirus Vectors by Peptide Ligand Insertion into Various Positions of the Adenovirus Serotype 41 Short-Fiber Knob Domain. Journal of Virology, 81, Article 6. https://doi.org/10.1128/JVI.02722-06
    10. Berg, D., Lehne, M., Müller, N., Siegmund, D., Münkel, S., Sebald, W., Pfizenmaier, K., & Wajant, H. (2007). Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death and Differentiation, 14, Article 12. https://doi.org/10.1038/sj.cdd.4402213
    11. Fugmann, T., Hausser, A., Schöffler, P., Schmid, S., Pfizenmaier, K., & Olayioye, M. A. (2007). Regulation of secretory transport by protein kinase D-mediated phosphorylation of the ceramide transfer protein. Journal of Cell Biology, 178, Article 1. https://doi.org/10.1083/jcb.200612017
    12. Müller, D., & Kontermann, R. E. (2007). Recombinant bispecific antibodies for cellular cancer immunotherapy. Current Opinion in Molecular Therapeutics, 9, Article 4. https://www.ncbi.nlm.nih.gov/pubmed/17694444
    13. Eiseler, T., Schmid, M. A., Topbas, F., Pfizenmaier, K., & Hausser, A. (2007). PKD is recruited to sites of actin remodelling at the leading edge and negatively regulates cell migration. FEBS Letters, 581, Article 22. https://doi.org/10.1016/j.febslet.2007.07.079
    14. Müller, D., Karle, A., Meißburger, B., Höfig, I., Stork, R., & Kontermann, R. E. (2007). Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. Journal of Biological Chemistry, 282, Article 17. https://doi.org/10.1074/jbc.M700820200
    15. Eißing, T., Waldherr, S., Allgöwer, F., Scheurich, P., & Bullinger, E. (2007). Steady state and (bi-) stability evaluation of simple protease signalling networks. Biosystems, 90, Article 3. https://doi.org/10.1016/j.biosystems.2007.01.003
    16. Eissing, T., Waldherr, S., Allgöwer, F., Scheurich, P., & Bullinger, E. (2007). Response to bistability in apoptosis: Roles of Bax, Bcl-2, and mitochondrial permeability transition pores. Biophysical Journal, 92, Article 9. https://doi.org/10.1529/biophysj.106.100362
    17. Huber, H., Estrada, G., Dussmann, H., connor, C., & Rehm, M. (2007). Extending the explanatory power of live cell imaging by computationally modelling the execution of apoptotic cell death (A. Méndez-Vilas & A. Diaz, Eds.; Vol. 1). Formatex.

  21. 2006

    1. Gerspach, J., Müller, D., Münkel, S., Selchow, O., Nemeth, J., Noack, M., Petrul, H., Menrad, A., Wajant, H., & Pfizenmaier, K. (2006). Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug. Cell Death and Differentiation, 13, Article 2. https://doi.org/10.1038/sj.cdd.4401735
    2. Hausser, A., Link, G., Hoene, M., Russo, C., Selchow, O., & Pfizenmaier, K. (2006). Phospho-specific binding of 14-3-3 proteins to phosphatidylinositol 4-kinase III β protects from dephosphorylation and stabilizes lipid kinase activity. Journal of Cell Science, 119, Article 17. https://doi.org/10.1242/jcs.03104
    3. Rüger, R., Müller, D., Fahr, A., & Kontermann, R. E. (2006). In vitro characterization of binding and stability of single-chain Fv Ni-NTA-liposomes. Journal of Drug Targeting, 14, Article 8. https://doi.org/10.1080/10611860600864018
    4. Kontermann, R. E. (2006). Immunoliposomes for cancer therapy. Current Opinion in Molecular Therapeutics, 8, Article 1. http://www.ncbi.nlm.nih.gov/pubmed/16506524
    5. Maier, D., Hausser, A., Nagel, A. C., Link, G., Kugler, S. J., Wech, I., Pfizenmaier, K., & Preiss, A. (2006). Drosophila protein kinase D is broadly expressed and a fraction localizes to the Golgi compartment. Gene Expression Patterns, 6, Article 8. https://doi.org/10.1016/j.modgep.2006.03.007
    6. Watermann, I., Gerspach, J., Lehne, M., Seufert, J., Schneider, B., Pfizenmaier, K., & Wajant, H. (2006). Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death and Differentiation, 14, 765––. http://dx.doi.org/10.1038/sj.cdd.4402051
    7. Strozyk, E., Pöppelmann, B., Schwarz, T., & Kulms, D. (2006). Differential effects of NF-κB on apoptosis induced by DNA-damaging agents: The type of DNA damage determines the final outcome. Oncogene, 25, Article 47. https://doi.org/10.1038/sj.onc.1209655
    8. Assohou-Luty, C., Gerspach, J., Siegmund, D., Müller, N., Huard, B., Tiegs, G., Pfizenmaier, K., & Wajant, H. (2006). A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. Journal of Molecular Medicine, 84, Article 9. https://doi.org/10.1007/s00109-006-0073-1
    9. Gerspach, J., Németh, J., Münkel, S., Wajant, H., & Pfizenmaier, K. (2006). Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface. Cancer Immunology, Immunotherapy, 55, Article 12. https://doi.org/10.1007/s00262-006-0162-6
    10. Kulms, D., & Schwarz, T. (2006). NF-κB and Cytokines. Vitamins and Hormones, 74, 283–300. https://doi.org/10.1016/S0083-6729(06)74011-0
    11. Beisner, J., Buck, M. B., Fritz, P., Dippon, J., Schwab, M., Brauch, H., Zugmaier, G., Pfizenmaier, K., & Knabbe, C. (2006). A Novel Functional Polymorphism in the Transforming Growth Factor-β2 Gene Promoter and Tumor Progression in Breast Cancer. Cancer Research, 66, Article 15. https://doi.org/10.1158/0008-5472.CAN-06-0634
To the top of the page